{"idB": "908259_12_item7_p8_s1", "idA": "908259_11_item7_p107_s2", "sentA": "In 2009, the gain primarily relates to the decline in the underlying fair value of the common stock.", "sentB": "Vascular disruption leads to tumor hypoxia, which refers to the process of starving the tumor of vitally necessary oxygen supply and subsequent tumor cell death.", "type": 1, "words": ["<tag1>", "In", "2009,", "the", "gain", "primarily", "relates", "to", "the", "decline", "in", "the", "underlying", "fair", "value", "of", "the", "common", "stock.", "<tag2>", "Vascular", "disruption", "leads", "to", "tumor", "hypoxia,", "which", "refers", "to", "the", "process", "of", "starving", "the", "tumor", "of", "vitally", "necessary", "oxygen", "supply", "and", "subsequent", "tumor", "cell", "death.", "<tag3>"], "wordsA": ["In", "2009,", "the", "gain", "primarily", "relates", "to", "the", "decline", "in", "the", "underlying", "fair", "value", "of", "the", "common", "stock."], "wordsB": ["Vascular", "disruption", "leads", "to", "tumor", "hypoxia,", "which", "refers", "to", "the", "process", "of", "starving", "the", "tumor", "of", "vitally", "necessary", "oxygen", "supply", "and", "subsequent", "tumor", "cell", "death."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p8_s2", "idA": "908259_11_item7_p107_s2", "sentA": "In 2009, the gain primarily relates to the decline in the underlying fair value of the common stock.", "sentB": "More specifically, ZYBRESTAT selectively targets the existing abnormal and largely immature vasculature found specifically in most solid tumors and causes endothelial cells that make up the walls of the blood vessels in that vasculature to lose their normally flat shape and to become round, thus blocking the flow of blood to the tumor.", "type": 1, "words": ["<tag1>", "In", "2009,", "the", "gain", "primarily", "relates", "to", "the", "decline", "in", "the", "underlying", "fair", "value", "of", "the", "common", "stock.", "<tag2>", "More", "specifically,", "ZYBRESTAT", "selectively", "targets", "the", "existing", "abnormal", "and", "largely", "immature", "vasculature", "found", "specifically", "in", "most", "solid", "tumors", "and", "causes", "endothelial", "cells", "that", "make", "up", "the", "walls", "of", "the", "blood", "vessels", "in", "that", "vasculature", "to", "lose", "their", "normally", "flat", "shape", "and", "to", "become", "round,", "thus", "blocking", "the", "flow", "of", "blood", "to", "the", "tumor.", "<tag3>"], "wordsA": ["In", "2009,", "the", "gain", "primarily", "relates", "to", "the", "decline", "in", "the", "underlying", "fair", "value", "of", "the", "common", "stock."], "wordsB": ["More", "specifically,", "ZYBRESTAT", "selectively", "targets", "the", "existing", "abnormal", "and", "largely", "immature", "vasculature", "found", "specifically", "in", "most", "solid", "tumors", "and", "causes", "endothelial", "cells", "that", "make", "up", "the", "walls", "of", "the", "blood", "vessels", "in", "that", "vasculature", "to", "lose", "their", "normally", "flat", "shape", "and", "to", "become", "round,", "thus", "blocking", "the", "flow", "of", "blood", "to", "the", "tumor."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p1_s0", "idA": "908259_11_item7_p117_s3", "sentA": "These costs included accounting, legal and printing costs incurred in preparation for the acquisition.", "sentB": "(1) The amount related to loss attributed to non controlling interest in Symphony ViDA, Inc. represents the loss for the Symphony ViDA, Inc. entity from its inception in October 2008 through the acquisition of the entity in July 2009.", "type": 1, "words": ["<tag1>", "These", "costs", "included", "accounting,", "legal", "and", "printing", "costs", "incurred", "in", "preparation", "for", "the", "acquisition.", "<tag2>", "(1)", "The", "amount", "related", "to", "loss", "attributed", "to", "non", "controlling", "interest", "in", "Symphony", "ViDA,", "Inc.", "represents", "the", "loss", "for", "the", "Symphony", "ViDA,", "Inc.", "entity", "from", "its", "inception", "in", "October", "2008", "through", "the", "acquisition", "of", "the", "entity", "in", "July", "2009.", "<tag3>"], "wordsA": ["These", "costs", "included", "accounting,", "legal", "and", "printing", "costs", "incurred", "in", "preparation", "for", "the", "acquisition."], "wordsB": ["(1)", "The", "amount", "related", "to", "loss", "attributed", "to", "non", "controlling", "interest", "in", "Symphony", "ViDA,", "Inc.", "represents", "the", "loss", "for", "the", "Symphony", "ViDA,", "Inc.", "entity", "from", "its", "inception", "in", "October", "2008", "through", "the", "acquisition", "of", "the", "entity", "in", "July", "2009."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p66_s1", "idA": "908259_11_item7_p129_s2", "sentA": "As our current ongoing trials proceed to completion, we expect the per quarter cash requirement to continue to decline to the $2,500,000 to $3,000,000 range over the course of 2011.", "sentB": "We intend to continue to explore options for conducting such a study, including obtaining financing from external sources as well as potential collaborations with national and international head and neck cancer cooperative groups.", "type": 1, "words": ["<tag1>", "As", "our", "current", "ongoing", "trials", "proceed", "to", "completion,", "we", "expect", "the", "per", "quarter", "cash", "requirement", "to", "continue", "to", "decline", "to", "the", "$2,500,000", "to", "$3,000,000", "range", "over", "the", "course", "of", "2011.", "<tag2>", "We", "intend", "to", "continue", "to", "explore", "options", "for", "conducting", "such", "a", "study,", "including", "obtaining", "financing", "from", "external", "sources", "as", "well", "as", "potential", "collaborations", "with", "national", "and", "international", "head", "and", "neck", "cancer", "cooperative", "groups.", "<tag3>"], "wordsA": ["As", "our", "current", "ongoing", "trials", "proceed", "to", "completion,", "we", "expect", "the", "per", "quarter", "cash", "requirement", "to", "continue", "to", "decline", "to", "the", "$2,500,000", "to", "$3,000,000", "range", "over", "the", "course", "of", "2011."], "wordsB": ["We", "intend", "to", "continue", "to", "explore", "options", "for", "conducting", "such", "a", "study,", "including", "obtaining", "financing", "from", "external", "sources", "as", "well", "as", "potential", "collaborations", "with", "national", "and", "international", "head", "and", "neck", "cancer", "cooperative", "groups."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p58_s3", "idA": "908259_11_item7_p143_s0", "sentA": "In January 2011, we sold the remaining 48,350 shares resulting in net proceeds to us of approximately $180,000.", "sentB": "If Azanta does not notify us of any defective product within the 30-day period it will be deemed to have accepted the product.", "type": 1, "words": ["<tag1>", "In", "January", "2011,", "we", "sold", "the", "remaining", "48,350", "shares", "resulting", "in", "net", "proceeds", "to", "us", "of", "approximately", "$180,000.", "<tag2>", "If", "Azanta", "does", "not", "notify", "us", "of", "any", "defective", "product", "within", "the", "30-day", "period", "it", "will", "be", "deemed", "to", "have", "accepted", "the", "product.", "<tag3>"], "wordsA": ["In", "January", "2011,", "we", "sold", "the", "remaining", "48,350", "shares", "resulting", "in", "net", "proceeds", "to", "us", "of", "approximately", "$180,000."], "wordsB": ["If", "Azanta", "does", "not", "notify", "us", "of", "any", "defective", "product", "within", "the", "30-day", "period", "it", "will", "be", "deemed", "to", "have", "accepted", "the", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p26_s0", "idA": "908259_11_item7_p144_s1", "sentA": "Currently, the ATM is our only source of capital to enable the continuation of our operations.", "sentB": "We are seeking to reduce the amount of space we currently rent, primarily by closing our office in Waltham, Massachusetts no later than the lease expiration in May 2012 and by conducting our operations only out of our South San Francisco office as soon as practicable.", "type": 1, "words": ["<tag1>", "Currently,", "the", "ATM", "is", "our", "only", "source", "of", "capital", "to", "enable", "the", "continuation", "of", "our", "operations.", "<tag2>", "We", "are", "seeking", "to", "reduce", "the", "amount", "of", "space", "we", "currently", "rent,", "primarily", "by", "closing", "our", "office", "in", "Waltham,", "Massachusetts", "no", "later", "than", "the", "lease", "expiration", "in", "May", "2012", "and", "by", "conducting", "our", "operations", "only", "out", "of", "our", "South", "San", "Francisco", "office", "as", "soon", "as", "practicable.", "<tag3>"], "wordsA": ["Currently,", "the", "ATM", "is", "our", "only", "source", "of", "capital", "to", "enable", "the", "continuation", "of", "our", "operations."], "wordsB": ["We", "are", "seeking", "to", "reduce", "the", "amount", "of", "space", "we", "currently", "rent,", "primarily", "by", "closing", "our", "office", "in", "Waltham,", "Massachusetts", "no", "later", "than", "the", "lease", "expiration", "in", "May", "2012", "and", "by", "conducting", "our", "operations", "only", "out", "of", "our", "South", "San", "Francisco", "office", "as", "soon", "as", "practicable."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p72_s0", "idA": "908259_11_item7_p144_s1", "sentA": "Currently, the ATM is our only source of capital to enable the continuation of our operations.", "sentB": "We are seeking to reduce the amount of space we currently rent, primarily by closing our office in Waltham, Massachusetts no later than the lease expiration in May 2012 and by conducting our operations only out of our South San Francisco office as soon as practicable.", "type": 1, "words": ["<tag1>", "Currently,", "the", "ATM", "is", "our", "only", "source", "of", "capital", "to", "enable", "the", "continuation", "of", "our", "operations.", "<tag2>", "We", "are", "seeking", "to", "reduce", "the", "amount", "of", "space", "we", "currently", "rent,", "primarily", "by", "closing", "our", "office", "in", "Waltham,", "Massachusetts", "no", "later", "than", "the", "lease", "expiration", "in", "May", "2012", "and", "by", "conducting", "our", "operations", "only", "out", "of", "our", "South", "San", "Francisco", "office", "as", "soon", "as", "practicable.", "<tag3>"], "wordsA": ["Currently,", "the", "ATM", "is", "our", "only", "source", "of", "capital", "to", "enable", "the", "continuation", "of", "our", "operations."], "wordsB": ["We", "are", "seeking", "to", "reduce", "the", "amount", "of", "space", "we", "currently", "rent,", "primarily", "by", "closing", "our", "office", "in", "Waltham,", "Massachusetts", "no", "later", "than", "the", "lease", "expiration", "in", "May", "2012", "and", "by", "conducting", "our", "operations", "only", "out", "of", "our", "South", "San", "Francisco", "office", "as", "soon", "as", "practicable."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p60_s1", "idA": "908259_11_item7_p148_s0", "sentA": "Shares have been issued to our directors under the Director Compensation policy as compensation for their board and committee services.", "sentB": "These two major studies have been progressing to conclusion over the last 12 to 18 months.", "type": 1, "words": ["<tag1>", "Shares", "have", "been", "issued", "to", "our", "directors", "under", "the", "Director", "Compensation", "policy", "as", "compensation", "for", "their", "board", "and", "committee", "services.", "<tag2>", "These", "two", "major", "studies", "have", "been", "progressing", "to", "conclusion", "over", "the", "last", "12", "to", "18", "months.", "<tag3>"], "wordsA": ["Shares", "have", "been", "issued", "to", "our", "directors", "under", "the", "Director", "Compensation", "policy", "as", "compensation", "for", "their", "board", "and", "committee", "services."], "wordsB": ["These", "two", "major", "studies", "have", "been", "progressing", "to", "conclusion", "over", "the", "last", "12", "to", "18", "months."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p102_s1", "idA": "908259_11_item7_p154_s2", "sentA": "Any additional equity financing may be dilutive to our current stockholders and debt financing, if available, may involve restrictive covenants.", "sentB": "The agreement may be terminated by us at any time, at our sole discretion, without any cost or penalty.", "type": 1, "words": ["<tag1>", "Any", "additional", "equity", "financing", "may", "be", "dilutive", "to", "our", "current", "stockholders", "and", "debt", "financing,", "if", "available,", "may", "involve", "restrictive", "covenants.", "<tag2>", "The", "agreement", "may", "be", "terminated", "by", "us", "at", "any", "time,", "at", "our", "sole", "discretion,", "without", "any", "cost", "or", "penalty.", "<tag3>"], "wordsA": ["Any", "additional", "equity", "financing", "may", "be", "dilutive", "to", "our", "current", "stockholders", "and", "debt", "financing,", "if", "available,", "may", "involve", "restrictive", "covenants."], "wordsB": ["The", "agreement", "may", "be", "terminated", "by", "us", "at", "any", "time,", "at", "our", "sole", "discretion,", "without", "any", "cost", "or", "penalty."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p28_s6", "idA": "908259_11_item7_p154_s2", "sentA": "Any additional equity financing may be dilutive to our current stockholders and debt financing, if available, may involve restrictive covenants.", "sentB": "The agreement may be terminated by us at any time, at our sole discretion, without any cost or penalty.", "type": 1, "words": ["<tag1>", "Any", "additional", "equity", "financing", "may", "be", "dilutive", "to", "our", "current", "stockholders", "and", "debt", "financing,", "if", "available,", "may", "involve", "restrictive", "covenants.", "<tag2>", "The", "agreement", "may", "be", "terminated", "by", "us", "at", "any", "time,", "at", "our", "sole", "discretion,", "without", "any", "cost", "or", "penalty.", "<tag3>"], "wordsA": ["Any", "additional", "equity", "financing", "may", "be", "dilutive", "to", "our", "current", "stockholders", "and", "debt", "financing,", "if", "available,", "may", "involve", "restrictive", "covenants."], "wordsB": ["The", "agreement", "may", "be", "terminated", "by", "us", "at", "any", "time,", "at", "our", "sole", "discretion,", "without", "any", "cost", "or", "penalty."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p30_s0", "idA": "908259_11_item7_p158_s5", "sentA": "The license agreement also provides for additional payments upon our election to develop certain additional compounds, as defined in the agreement.", "sentB": "the territory covered by the agreement until such time as ZYBRESTAT may obtain marketing approval in that territory.", "type": 1, "words": ["<tag1>", "The", "license", "agreement", "also", "provides", "for", "additional", "payments", "upon", "our", "election", "to", "develop", "certain", "additional", "compounds,", "as", "defined", "in", "the", "agreement.", "<tag2>", "the", "territory", "covered", "by", "the", "agreement", "until", "such", "time", "as", "ZYBRESTAT", "may", "obtain", "marketing", "approval", "in", "that", "territory.", "<tag3>"], "wordsA": ["The", "license", "agreement", "also", "provides", "for", "additional", "payments", "upon", "our", "election", "to", "develop", "certain", "additional", "compounds,", "as", "defined", "in", "the", "agreement."], "wordsB": ["the", "territory", "covered", "by", "the", "agreement", "until", "such", "time", "as", "ZYBRESTAT", "may", "obtain", "marketing", "approval", "in", "that", "territory."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p103_s1", "idA": "908259_11_item7_p15_s1", "sentA": "We will provide ZYBRESTAT to NCI for an NCI-sponsored study conducted by the Gynecologic Oncology Group (GOG), an organization dedicated to clinical research in the field of gynecologic cancer.", "sentB": "Our newly-formed Named Patient Program to be managed by Azanta provides a regulatory mechanism to allow healthcare professionals in the territory to prescribe ZYBRESTAT to individual ATC patients while it is still in development.", "type": 1, "words": ["<tag1>", "We", "will", "provide", "ZYBRESTAT", "to", "NCI", "for", "an", "NCI-sponsored", "study", "conducted", "by", "the", "Gynecologic", "Oncology", "Group", "(GOG),", "an", "organization", "dedicated", "to", "clinical", "research", "in", "the", "field", "of", "gynecologic", "cancer.", "<tag2>", "Our", "newly-formed", "Named", "Patient", "Program", "to", "be", "managed", "by", "Azanta", "provides", "a", "regulatory", "mechanism", "to", "allow", "healthcare", "professionals", "in", "the", "territory", "to", "prescribe", "ZYBRESTAT", "to", "individual", "ATC", "patients", "while", "it", "is", "still", "in", "development.", "<tag3>"], "wordsA": ["We", "will", "provide", "ZYBRESTAT", "to", "NCI", "for", "an", "NCI-sponsored", "study", "conducted", "by", "the", "Gynecologic", "Oncology", "Group", "(GOG),", "an", "organization", "dedicated", "to", "clinical", "research", "in", "the", "field", "of", "gynecologic", "cancer."], "wordsB": ["Our", "newly-formed", "Named", "Patient", "Program", "to", "be", "managed", "by", "Azanta", "provides", "a", "regulatory", "mechanism", "to", "allow", "healthcare", "professionals", "in", "the", "territory", "to", "prescribe", "ZYBRESTAT", "to", "individual", "ATC", "patients", "while", "it", "is", "still", "in", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p5_s0", "idA": "908259_11_item7_p1_s0", "sentA": "We are a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases.", "sentB": "The Orphan Drug Act was passed in January 1983 to stimulate the research, development, and approval of products that treat rare diseases.", "type": 1, "words": ["<tag1>", "We", "are", "a", "clinical-stage,", "biopharmaceutical", "company", "developing", "novel", "therapeutics", "to", "treat", "cancer", "and", "eye", "diseases.", "<tag2>", "The", "Orphan", "Drug", "Act", "was", "passed", "in", "January", "1983", "to", "stimulate", "the", "research,", "development,", "and", "approval", "of", "products", "that", "treat", "rare", "diseases.", "<tag3>"], "wordsA": ["We", "are", "a", "clinical-stage,", "biopharmaceutical", "company", "developing", "novel", "therapeutics", "to", "treat", "cancer", "and", "eye", "diseases."], "wordsB": ["The", "Orphan", "Drug", "Act", "was", "passed", "in", "January", "1983", "to", "stimulate", "the", "research,", "development,", "and", "approval", "of", "products", "that", "treat", "rare", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p8_s0", "idA": "908259_11_item7_p1_s1", "sentA": "Our primary focus is the development of product candidates referred to as vascular disrupting agents, or VDAs, that selectively disable and destroy abnormal blood vessels that provide solid tumors a means of growth and survival and also are associated with visual impairment in a number of ophthalmological diseases and conditions.", "sentB": "ZYBRESTAT for Oncology ZYBRESTAT is a reversible tubulin binding agent that works by disrupting the network of blood vessels, or vasculature, within solid tumors, also referred to as vascular disruption.", "type": 1, "words": ["<tag1>", "Our", "primary", "focus", "is", "the", "development", "of", "product", "candidates", "referred", "to", "as", "vascular", "disrupting", "agents,", "or", "VDAs,", "that", "selectively", "disable", "and", "destroy", "abnormal", "blood", "vessels", "that", "provide", "solid", "tumors", "a", "means", "of", "growth", "and", "survival", "and", "also", "are", "associated", "with", "visual", "impairment", "in", "a", "number", "of", "ophthalmological", "diseases", "and", "conditions.", "<tag2>", "ZYBRESTAT", "for", "Oncology", "ZYBRESTAT", "is", "a", "reversible", "tubulin", "binding", "agent", "that", "works", "by", "disrupting", "the", "network", "of", "blood", "vessels,", "or", "vasculature,", "within", "solid", "tumors,", "also", "referred", "to", "as", "vascular", "disruption.", "<tag3>"], "wordsA": ["Our", "primary", "focus", "is", "the", "development", "of", "product", "candidates", "referred", "to", "as", "vascular", "disrupting", "agents,", "or", "VDAs,", "that", "selectively", "disable", "and", "destroy", "abnormal", "blood", "vessels", "that", "provide", "solid", "tumors", "a", "means", "of", "growth", "and", "survival", "and", "also", "are", "associated", "with", "visual", "impairment", "in", "a", "number", "of", "ophthalmological", "diseases", "and", "conditions."], "wordsB": ["ZYBRESTAT", "for", "Oncology", "ZYBRESTAT", "is", "a", "reversible", "tubulin", "binding", "agent", "that", "works", "by", "disrupting", "the", "network", "of", "blood", "vessels,", "or", "vasculature,", "within", "solid", "tumors,", "also", "referred", "to", "as", "vascular", "disruption."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p17_s1", "idA": "908259_11_item7_p22_s4", "sentA": "OXi4503 was also observed to be well-tolerated in this study.", "sentB": "Due to financial constraints, we are not actively pursuing development in this area at this time.", "type": 1, "words": ["<tag1>", "OXi4503", "was", "also", "observed", "to", "be", "well-tolerated", "in", "this", "study.", "<tag2>", "Due", "to", "financial", "constraints,", "we", "are", "not", "actively", "pursuing", "development", "in", "this", "area", "at", "this", "time.", "<tag3>"], "wordsA": ["OXi4503", "was", "also", "observed", "to", "be", "well-tolerated", "in", "this", "study."], "wordsB": ["Due", "to", "financial", "constraints,", "we", "are", "not", "actively", "pursuing", "development", "in", "this", "area", "at", "this", "time."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p29_s1", "idA": "908259_11_item7_p22_s4", "sentA": "OXi4503 was also observed to be well-tolerated in this study.", "sentB": "Our newly-formed Named Patient Program to be managed by Azanta, provides a regulatory mechanism to allow healthcare professionals in Europe and Canada to prescribe ZYBRESTAT to individual ATC patients while it is still in development.", "type": 1, "words": ["<tag1>", "OXi4503", "was", "also", "observed", "to", "be", "well-tolerated", "in", "this", "study.", "<tag2>", "Our", "newly-formed", "Named", "Patient", "Program", "to", "be", "managed", "by", "Azanta,", "provides", "a", "regulatory", "mechanism", "to", "allow", "healthcare", "professionals", "in", "Europe", "and", "Canada", "to", "prescribe", "ZYBRESTAT", "to", "individual", "ATC", "patients", "while", "it", "is", "still", "in", "development.", "<tag3>"], "wordsA": ["OXi4503", "was", "also", "observed", "to", "be", "well-tolerated", "in", "this", "study."], "wordsB": ["Our", "newly-formed", "Named", "Patient", "Program", "to", "be", "managed", "by", "Azanta,", "provides", "a", "regulatory", "mechanism", "to", "allow", "healthcare", "professionals", "in", "Europe", "and", "Canada", "to", "prescribe", "ZYBRESTAT", "to", "individual", "ATC", "patients", "while", "it", "is", "still", "in", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p58_s1", "idA": "908259_11_item7_p22_s4", "sentA": "OXi4503 was also observed to be well-tolerated in this study.", "sentB": "Our newly-formed Named Patient Program to be managed by Azanta, provides a regulatory mechanism to allow healthcare professionals in Europe and Canada to prescribe ZYBRESTAT to individual ATC patients while it is still in development.", "type": 1, "words": ["<tag1>", "OXi4503", "was", "also", "observed", "to", "be", "well-tolerated", "in", "this", "study.", "<tag2>", "Our", "newly-formed", "Named", "Patient", "Program", "to", "be", "managed", "by", "Azanta,", "provides", "a", "regulatory", "mechanism", "to", "allow", "healthcare", "professionals", "in", "Europe", "and", "Canada", "to", "prescribe", "ZYBRESTAT", "to", "individual", "ATC", "patients", "while", "it", "is", "still", "in", "development.", "<tag3>"], "wordsA": ["OXi4503", "was", "also", "observed", "to", "be", "well-tolerated", "in", "this", "study."], "wordsB": ["Our", "newly-formed", "Named", "Patient", "Program", "to", "be", "managed", "by", "Azanta,", "provides", "a", "regulatory", "mechanism", "to", "allow", "healthcare", "professionals", "in", "Europe", "and", "Canada", "to", "prescribe", "ZYBRESTAT", "to", "individual", "ATC", "patients", "while", "it", "is", "still", "in", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p20_s1", "idA": "908259_11_item7_p37_s2", "sentA": "As our current ongoing trials proceed to completion, we expect the per quarter cash requirement to continue to decline to the $2,500,000 to $3,000,000 range over the course of 2011.", "sentB": "We intend to continue to explore options for conducting such a study, including potential collaborations with national and international head and neck cancer cooperative groups.", "type": 1, "words": ["<tag1>", "As", "our", "current", "ongoing", "trials", "proceed", "to", "completion,", "we", "expect", "the", "per", "quarter", "cash", "requirement", "to", "continue", "to", "decline", "to", "the", "$2,500,000", "to", "$3,000,000", "range", "over", "the", "course", "of", "2011.", "<tag2>", "We", "intend", "to", "continue", "to", "explore", "options", "for", "conducting", "such", "a", "study,", "including", "potential", "collaborations", "with", "national", "and", "international", "head", "and", "neck", "cancer", "cooperative", "groups.", "<tag3>"], "wordsA": ["As", "our", "current", "ongoing", "trials", "proceed", "to", "completion,", "we", "expect", "the", "per", "quarter", "cash", "requirement", "to", "continue", "to", "decline", "to", "the", "$2,500,000", "to", "$3,000,000", "range", "over", "the", "course", "of", "2011."], "wordsB": ["We", "intend", "to", "continue", "to", "explore", "options", "for", "conducting", "such", "a", "study,", "including", "potential", "collaborations", "with", "national", "and", "international", "head", "and", "neck", "cancer", "cooperative", "groups."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p6_s1", "idA": "908259_11_item7_p41_s2", "sentA": "In connection with the CEFF, in 2008, we issued a warrant to Kingsbridge to purchase 12,500 shares of our common stock at a price of $54.80 per share exercisable beginning six months after February 19, 2008 for a period of five years thereafter.", "sentB": "Drugs are granted orphan status for a specific indication.", "type": 1, "words": ["<tag1>", "In", "connection", "with", "the", "CEFF,", "in", "2008,", "we", "issued", "a", "warrant", "to", "Kingsbridge", "to", "purchase", "12,500", "shares", "of", "our", "common", "stock", "at", "a", "price", "of", "$54.80", "per", "share", "exercisable", "beginning", "six", "months", "after", "February", "19,", "2008", "for", "a", "period", "of", "five", "years", "thereafter.", "<tag2>", "Drugs", "are", "granted", "orphan", "status", "for", "a", "specific", "indication.", "<tag3>"], "wordsA": ["In", "connection", "with", "the", "CEFF,", "in", "2008,", "we", "issued", "a", "warrant", "to", "Kingsbridge", "to", "purchase", "12,500", "shares", "of", "our", "common", "stock", "at", "a", "price", "of", "$54.80", "per", "share", "exercisable", "beginning", "six", "months", "after", "February", "19,", "2008", "for", "a", "period", "of", "five", "years", "thereafter."], "wordsB": ["Drugs", "are", "granted", "orphan", "status", "for", "a", "specific", "indication."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p109_s1", "idA": "908259_11_item7_p53_s0", "sentA": "We have no significant off balance sheet concentrations of credit risk.", "sentB": "Although our investments are subject to credit risk, we follow procedures to limit the amount of credit exposure in any single issue, issuer or type of investment.", "type": 1, "words": ["<tag1>", "We", "have", "no", "significant", "off", "balance", "sheet", "concentrations", "of", "credit", "risk.", "<tag2>", "Although", "our", "investments", "are", "subject", "to", "credit", "risk,", "we", "follow", "procedures", "to", "limit", "the", "amount", "of", "credit", "exposure", "in", "any", "single", "issue,", "issuer", "or", "type", "of", "investment.", "<tag3>"], "wordsA": ["We", "have", "no", "significant", "off", "balance", "sheet", "concentrations", "of", "credit", "risk."], "wordsB": ["Although", "our", "investments", "are", "subject", "to", "credit", "risk,", "we", "follow", "procedures", "to", "limit", "the", "amount", "of", "credit", "exposure", "in", "any", "single", "issue,", "issuer", "or", "type", "of", "investment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p11_s2", "idA": "908259_11_item7_p54_s1", "sentA": "We have $75,000 that is used to secure financing through a Company credit card.", "sentB": "As such, our primary corporate strategy for 2012 is to secure sufficient funding to conduct the trial.", "type": 1, "words": ["<tag1>", "We", "have", "$75,000", "that", "is", "used", "to", "secure", "financing", "through", "a", "Company", "credit", "card.", "<tag2>", "As", "such,", "our", "primary", "corporate", "strategy", "for", "2012", "is", "to", "secure", "sufficient", "funding", "to", "conduct", "the", "trial.", "<tag3>"], "wordsA": ["We", "have", "$75,000", "that", "is", "used", "to", "secure", "financing", "through", "a", "Company", "credit", "card."], "wordsB": ["As", "such,", "our", "primary", "corporate", "strategy", "for", "2012", "is", "to", "secure", "sufficient", "funding", "to", "conduct", "the", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p103_s4", "idA": "908259_11_item7_p55_s2", "sentA": "We review the status of the unrealized gains and losses of our available-for-sale marketable securities on a regular basis.", "sentB": "The territory includes the European Union, including the Nordic countries and Switzerland, and Canada, and the agreement may also be expanded to include other countries on a country-by-country basis.", "type": 1, "words": ["<tag1>", "We", "review", "the", "status", "of", "the", "unrealized", "gains", "and", "losses", "of", "our", "available-for-sale", "marketable", "securities", "on", "a", "regular", "basis.", "<tag2>", "The", "territory", "includes", "the", "European", "Union,", "including", "the", "Nordic", "countries", "and", "Switzerland,", "and", "Canada,", "and", "the", "agreement", "may", "also", "be", "expanded", "to", "include", "other", "countries", "on", "a", "country-by-country", "basis.", "<tag3>"], "wordsA": ["We", "review", "the", "status", "of", "the", "unrealized", "gains", "and", "losses", "of", "our", "available-for-sale", "marketable", "securities", "on", "a", "regular", "basis."], "wordsB": ["The", "territory", "includes", "the", "European", "Union,", "including", "the", "Nordic", "countries", "and", "Switzerland,", "and", "Canada,", "and", "the", "agreement", "may", "also", "be", "expanded", "to", "include", "other", "countries", "on", "a", "country-by-country", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p30_s1", "idA": "908259_11_item7_p55_s2", "sentA": "We review the status of the unrealized gains and losses of our available-for-sale marketable securities on a regular basis.", "sentB": "The territory includes the European Union, including the Nordic countries and Switzerland, and Canada, and the agreement may also be expanded to include other countries on a country-by-country basis.", "type": 1, "words": ["<tag1>", "We", "review", "the", "status", "of", "the", "unrealized", "gains", "and", "losses", "of", "our", "available-for-sale", "marketable", "securities", "on", "a", "regular", "basis.", "<tag2>", "The", "territory", "includes", "the", "European", "Union,", "including", "the", "Nordic", "countries", "and", "Switzerland,", "and", "Canada,", "and", "the", "agreement", "may", "also", "be", "expanded", "to", "include", "other", "countries", "on", "a", "country-by-country", "basis.", "<tag3>"], "wordsA": ["We", "review", "the", "status", "of", "the", "unrealized", "gains", "and", "losses", "of", "our", "available-for-sale", "marketable", "securities", "on", "a", "regular", "basis."], "wordsB": ["The", "territory", "includes", "the", "European", "Union,", "including", "the", "Nordic", "countries", "and", "Switzerland,", "and", "Canada,", "and", "the", "agreement", "may", "also", "be", "expanded", "to", "include", "other", "countries", "on", "a", "country-by-country", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p109_s2", "idA": "908259_11_item7_p63_s0", "sentA": "the risk free interest rate for the expected option term.", "sentB": "Our investments are also subject to interest rate risk and will decrease in value if market interest rates increase.", "type": 1, "words": ["<tag1>", "the", "risk", "free", "interest", "rate", "for", "the", "expected", "option", "term.", "<tag2>", "Our", "investments", "are", "also", "subject", "to", "interest", "rate", "risk", "and", "will", "decrease", "in", "value", "if", "market", "interest", "rates", "increase.", "<tag3>"], "wordsA": ["the", "risk", "free", "interest", "rate", "for", "the", "expected", "option", "term."], "wordsB": ["Our", "investments", "are", "also", "subject", "to", "interest", "rate", "risk", "and", "will", "decrease", "in", "value", "if", "market", "interest", "rates", "increase."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p109_s0", "idA": "908259_11_item7_p79_s3", "sentA": "Further, due to the direct investment from Holdings in our common stock, as a related party ViDA was a VIE of which we were the primary beneficiary.", "sentB": "We have adopted an Investment Policy, the primary objectives of which are to preserve principal, maintain proper liquidity to meet operating needs and maximize yields while preserving principal.", "type": 1, "words": ["<tag1>", "Further,", "due", "to", "the", "direct", "investment", "from", "Holdings", "in", "our", "common", "stock,", "as", "a", "related", "party", "ViDA", "was", "a", "VIE", "of", "which", "we", "were", "the", "primary", "beneficiary.", "<tag2>", "We", "have", "adopted", "an", "Investment", "Policy,", "the", "primary", "objectives", "of", "which", "are", "to", "preserve", "principal,", "maintain", "proper", "liquidity", "to", "meet", "operating", "needs", "and", "maximize", "yields", "while", "preserving", "principal.", "<tag3>"], "wordsA": ["Further,", "due", "to", "the", "direct", "investment", "from", "Holdings", "in", "our", "common", "stock,", "as", "a", "related", "party", "ViDA", "was", "a", "VIE", "of", "which", "we", "were", "the", "primary", "beneficiary."], "wordsB": ["We", "have", "adopted", "an", "Investment", "Policy,", "the", "primary", "objectives", "of", "which", "are", "to", "preserve", "principal,", "maintain", "proper", "liquidity", "to", "meet", "operating", "needs", "and", "maximize", "yields", "while", "preserving", "principal."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p58_s2", "idA": "908259_11_item7_p87_s0", "sentA": "Our future revenues will depend upon our ability to establish collaborations with respect to, and generate revenues from products currently under development by us.", "sentB": "Our agreement with Azanta provides that upon the receipt of ZYBRESTAT by Azanta for distribution and sale to compassionate use patients, Azanta has 30 days to inspect the product for defects and to ensure that the product conforms to the warranties made by us.", "type": 1, "words": ["<tag1>", "Our", "future", "revenues", "will", "depend", "upon", "our", "ability", "to", "establish", "collaborations", "with", "respect", "to,", "and", "generate", "revenues", "from", "products", "currently", "under", "development", "by", "us.", "<tag2>", "Our", "agreement", "with", "Azanta", "provides", "that", "upon", "the", "receipt", "of", "ZYBRESTAT", "by", "Azanta", "for", "distribution", "and", "sale", "to", "compassionate", "use", "patients,", "Azanta", "has", "30", "days", "to", "inspect", "the", "product", "for", "defects", "and", "to", "ensure", "that", "the", "product", "conforms", "to", "the", "warranties", "made", "by", "us.", "<tag3>"], "wordsA": ["Our", "future", "revenues", "will", "depend", "upon", "our", "ability", "to", "establish", "collaborations", "with", "respect", "to,", "and", "generate", "revenues", "from", "products", "currently", "under", "development", "by", "us."], "wordsB": ["Our", "agreement", "with", "Azanta", "provides", "that", "upon", "the", "receipt", "of", "ZYBRESTAT", "by", "Azanta", "for", "distribution", "and", "sale", "to", "compassionate", "use", "patients,", "Azanta", "has", "30", "days", "to", "inspect", "the", "product", "for", "defects", "and", "to", "ensure", "that", "the", "product", "conforms", "to", "the", "warranties", "made", "by", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_12_item7_p64_s2", "idA": "908259_11_item7_p98_s1", "sentA": "that did not recur in the 2010 period.", "sentB": "Also, we recognized lower legal, accounting and service provider expenses due to fewer significant transactions during the 2011 period.", "type": 1, "words": ["<tag1>", "that", "did", "not", "recur", "in", "the", "2010", "period.", "<tag2>", "Also,", "we", "recognized", "lower", "legal,", "accounting", "and", "service", "provider", "expenses", "due", "to", "fewer", "significant", "transactions", "during", "the", "2011", "period.", "<tag3>"], "wordsA": ["that", "did", "not", "recur", "in", "the", "2010", "period."], "wordsB": ["Also,", "we", "recognized", "lower", "legal,", "accounting", "and", "service", "provider", "expenses", "due", "to", "fewer", "significant", "transactions", "during", "the", "2011", "period."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_13_item7_p34_s8", "idA": "908259_12_item7_p103_s2", "sentA": "Under the terms of the agreement, we will provide ZYBRESTAT to Azanta.", "sentB": "Under the BMS license, we have the right to grant sublicenses.", "type": 1, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "will", "provide", "ZYBRESTAT", "to", "Azanta.", "<tag2>", "Under", "the", "BMS", "license,", "we", "have", "the", "right", "to", "grant", "sublicenses.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "will", "provide", "ZYBRESTAT", "to", "Azanta."], "wordsB": ["Under", "the", "BMS", "license,", "we", "have", "the", "right", "to", "grant", "sublicenses."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_13_item7_p13_s12", "idA": "908259_12_item7_p17_s8", "sentA": "We currently have no recurring material amount of licensing or other income.", "sentB": "In 2013, we expect approximately the same levels of revenue as 2012, although there can be no assurance of this and at this time, we have no future firm orders from Azanta.", "type": 1, "words": ["<tag1>", "We", "currently", "have", "no", "recurring", "material", "amount", "of", "licensing", "or", "other", "income.", "<tag2>", "In", "2013,", "we", "expect", "approximately", "the", "same", "levels", "of", "revenue", "as", "2012,", "although", "there", "can", "be", "no", "assurance", "of", "this", "and", "at", "this", "time,", "we", "have", "no", "future", "firm", "orders", "from", "Azanta.", "<tag3>"], "wordsA": ["We", "currently", "have", "no", "recurring", "material", "amount", "of", "licensing", "or", "other", "income."], "wordsB": ["In", "2013,", "we", "expect", "approximately", "the", "same", "levels", "of", "revenue", "as", "2012,", "although", "there", "can", "be", "no", "assurance", "of", "this", "and", "at", "this", "time,", "we", "have", "no", "future", "firm", "orders", "from", "Azanta."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_13_item7_p35_s0", "idA": "908259_12_item7_p30_s0", "sentA": "the territory covered by the agreement until such time as ZYBRESTAT may obtain marketing approval in that territory.", "sentB": "We bear the costs of preparing, filing, prosecuting and maintaining all patent applications under the BMS license and have a right, but not a duty, of enforcing patents covered by the license.", "type": 1, "words": ["<tag1>", "the", "territory", "covered", "by", "the", "agreement", "until", "such", "time", "as", "ZYBRESTAT", "may", "obtain", "marketing", "approval", "in", "that", "territory.", "<tag2>", "We", "bear", "the", "costs", "of", "preparing,", "filing,", "prosecuting", "and", "maintaining", "all", "patent", "applications", "under", "the", "BMS", "license", "and", "have", "a", "right,", "but", "not", "a", "duty,", "of", "enforcing", "patents", "covered", "by", "the", "license.", "<tag3>"], "wordsA": ["the", "territory", "covered", "by", "the", "agreement", "until", "such", "time", "as", "ZYBRESTAT", "may", "obtain", "marketing", "approval", "in", "that", "territory."], "wordsB": ["We", "bear", "the", "costs", "of", "preparing,", "filing,", "prosecuting", "and", "maintaining", "all", "patent", "applications", "under", "the", "BMS", "license", "and", "have", "a", "right,", "but", "not", "a", "duty,", "of", "enforcing", "patents", "covered", "by", "the", "license."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_13_item7_p34_s9", "idA": "908259_12_item7_p58_s2", "sentA": "Our agreement with Azanta provides that upon the receipt of ZYBRESTAT by Azanta for distribution and sale to compassionate use patients, Azanta has 30 days to inspect the product for defects and to ensure that the product conforms to the warranties made by us.", "sentB": "Under the license agreement, BMS is entitled to low-single-digit royalty payments for all commercial sales plus any remuneration OXiGENE receives for sale of ZYBRESTAT under named patient or compassionate use programs.", "type": 1, "words": ["<tag1>", "Our", "agreement", "with", "Azanta", "provides", "that", "upon", "the", "receipt", "of", "ZYBRESTAT", "by", "Azanta", "for", "distribution", "and", "sale", "to", "compassionate", "use", "patients,", "Azanta", "has", "30", "days", "to", "inspect", "the", "product", "for", "defects", "and", "to", "ensure", "that", "the", "product", "conforms", "to", "the", "warranties", "made", "by", "us.", "<tag2>", "Under", "the", "license", "agreement,", "BMS", "is", "entitled", "to", "low-single-digit", "royalty", "payments", "for", "all", "commercial", "sales", "plus", "any", "remuneration", "OXiGENE", "receives", "for", "sale", "of", "ZYBRESTAT", "under", "named", "patient", "or", "compassionate", "use", "programs.", "<tag3>"], "wordsA": ["Our", "agreement", "with", "Azanta", "provides", "that", "upon", "the", "receipt", "of", "ZYBRESTAT", "by", "Azanta", "for", "distribution", "and", "sale", "to", "compassionate", "use", "patients,", "Azanta", "has", "30", "days", "to", "inspect", "the", "product", "for", "defects", "and", "to", "ensure", "that", "the", "product", "conforms", "to", "the", "warranties", "made", "by", "us."], "wordsB": ["Under", "the", "license", "agreement,", "BMS", "is", "entitled", "to", "low-single-digit", "royalty", "payments", "for", "all", "commercial", "sales", "plus", "any", "remuneration", "OXiGENE", "receives", "for", "sale", "of", "ZYBRESTAT", "under", "named", "patient", "or", "compassionate", "use", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_13_item7_p15_s0", "idA": "908259_12_item7_p59_s0", "sentA": "Revenue is recognized under this agreement when payments are received due to the uncertainty of the timing of sales of products or services.", "sentB": "External services include clinical research organizations, clinical site services, labs, clinical manufacturing and many other outside services.", "type": 1, "words": ["<tag1>", "Revenue", "is", "recognized", "under", "this", "agreement", "when", "payments", "are", "received", "due", "to", "the", "uncertainty", "of", "the", "timing", "of", "sales", "of", "products", "or", "services.", "<tag2>", "External", "services", "include", "clinical", "research", "organizations,", "clinical", "site", "services,", "labs,", "clinical", "manufacturing", "and", "many", "other", "outside", "services.", "<tag3>"], "wordsA": ["Revenue", "is", "recognized", "under", "this", "agreement", "when", "payments", "are", "received", "due", "to", "the", "uncertainty", "of", "the", "timing", "of", "sales", "of", "products", "or", "services."], "wordsB": ["External", "services", "include", "clinical", "research", "organizations,", "clinical", "site", "services,", "labs,", "clinical", "manufacturing", "and", "many", "other", "outside", "services."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_13_item7_p18_s7", "idA": "908259_12_item7_p61_s2", "sentA": "General and administrative expenses The table below summarizes the most significant components of our general and administrative expenses for the periods indicated, in thousands and as a percentage of total general and administrative expenses and provides the changes in these components and their percentages:", "sentB": "We continue to evaluate general and administrative expense and look for ways to decrease such costs.", "type": 1, "words": ["<tag1>", "General", "and", "administrative", "expenses", "The", "table", "below", "summarizes", "the", "most", "significant", "components", "of", "our", "general", "and", "administrative", "expenses", "for", "the", "periods", "indicated,", "in", "thousands", "and", "as", "a", "percentage", "of", "total", "general", "and", "administrative", "expenses", "and", "provides", "the", "changes", "in", "these", "components", "and", "their", "percentages:", "<tag2>", "We", "continue", "to", "evaluate", "general", "and", "administrative", "expense", "and", "look", "for", "ways", "to", "decrease", "such", "costs.", "<tag3>"], "wordsA": ["General", "and", "administrative", "expenses", "The", "table", "below", "summarizes", "the", "most", "significant", "components", "of", "our", "general", "and", "administrative", "expenses", "for", "the", "periods", "indicated,", "in", "thousands", "and", "as", "a", "percentage", "of", "total", "general", "and", "administrative", "expenses", "and", "provides", "the", "changes", "in", "these", "components", "and", "their", "percentages:"], "wordsB": ["We", "continue", "to", "evaluate", "general", "and", "administrative", "expense", "and", "look", "for", "ways", "to", "decrease", "such", "costs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_13_item7_p13_s10", "idA": "908259_12_item7_p7_s0", "sentA": "To date, more than 400 subjects have been treated with ZYBRESTAT in human clinical trials, and the drug candidate has generally been observed to be well-tolerated.", "sentB": "We recognized approximately $148,000 of product revenues in 2012, after delivery of our drug for compassionate use to Azanta and the 30 day inspection period had expired at which point the drug was deemed accepted.", "type": 1, "words": ["<tag1>", "To", "date,", "more", "than", "400", "subjects", "have", "been", "treated", "with", "ZYBRESTAT", "in", "human", "clinical", "trials,", "and", "the", "drug", "candidate", "has", "generally", "been", "observed", "to", "be", "well-tolerated.", "<tag2>", "We", "recognized", "approximately", "$148,000", "of", "product", "revenues", "in", "2012,", "after", "delivery", "of", "our", "drug", "for", "compassionate", "use", "to", "Azanta", "and", "the", "30", "day", "inspection", "period", "had", "expired", "at", "which", "point", "the", "drug", "was", "deemed", "accepted.", "<tag3>"], "wordsA": ["To", "date,", "more", "than", "400", "subjects", "have", "been", "treated", "with", "ZYBRESTAT", "in", "human", "clinical", "trials,", "and", "the", "drug", "candidate", "has", "generally", "been", "observed", "to", "be", "well-tolerated."], "wordsB": ["We", "recognized", "approximately", "$148,000", "of", "product", "revenues", "in", "2012,", "after", "delivery", "of", "our", "drug", "for", "compassionate", "use", "to", "Azanta", "and", "the", "30", "day", "inspection", "period", "had", "expired", "at", "which", "point", "the", "drug", "was", "deemed", "accepted."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_13_item7_p16_s9", "idA": "908259_12_item7_p91_s0", "sentA": "We discontinued enrolling patients in our OXi4503 Phase 1b trial in patients with hepatic tumors.", "sentB": "We plan to begin new clinical trials in our oncology program, however, these studies are dependent upon receiving funding.", "type": 1, "words": ["<tag1>", "We", "discontinued", "enrolling", "patients", "in", "our", "OXi4503", "Phase", "1b", "trial", "in", "patients", "with", "hepatic", "tumors.", "<tag2>", "We", "plan", "to", "begin", "new", "clinical", "trials", "in", "our", "oncology", "program,", "however,", "these", "studies", "are", "dependent", "upon", "receiving", "funding.", "<tag3>"], "wordsA": ["We", "discontinued", "enrolling", "patients", "in", "our", "OXi4503", "Phase", "1b", "trial", "in", "patients", "with", "hepatic", "tumors."], "wordsB": ["We", "plan", "to", "begin", "new", "clinical", "trials", "in", "our", "oncology", "program,", "however,", "these", "studies", "are", "dependent", "upon", "receiving", "funding."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_13_item7_p1_s3", "idA": "908259_12_item7_p9_s1", "sentA": "Our top priority is to pursue the clinical development of ZYBRESTAT in ATC.", "sentB": "Our primary focus has been our ZYBRESTAT in oncology program.", "type": 1, "words": ["<tag1>", "Our", "top", "priority", "is", "to", "pursue", "the", "clinical", "development", "of", "ZYBRESTAT", "in", "ATC.", "<tag2>", "Our", "primary", "focus", "has", "been", "our", "ZYBRESTAT", "in", "oncology", "program.", "<tag3>"], "wordsA": ["Our", "top", "priority", "is", "to", "pursue", "the", "clinical", "development", "of", "ZYBRESTAT", "in", "ATC."], "wordsB": ["Our", "primary", "focus", "has", "been", "our", "ZYBRESTAT", "in", "oncology", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item7_p33_s2", "idA": "908259_13_item7_p13_s11", "sentA": "Additionally, we recognized approximately $8,000 as payment for 20% of Azanta s gross margin, as defined in the agreement, on its sales in the preceding quarter, in 2012, after Azanta notified us of the amount.", "sentB": "The Series A Preferred Stock contained a beneficial conversion feature and, as a result, we recognized approximately $2.48 million as a non-cash deemed dividend.", "type": 1, "words": ["<tag1>", "Additionally,", "we", "recognized", "approximately", "$8,000", "as", "payment", "for", "20%", "of", "Azanta", "s", "gross", "margin,", "as", "defined", "in", "the", "agreement,", "on", "its", "sales", "in", "the", "preceding", "quarter,", "in", "2012,", "after", "Azanta", "notified", "us", "of", "the", "amount.", "<tag2>", "The", "Series", "A", "Preferred", "Stock", "contained", "a", "beneficial", "conversion", "feature", "and,", "as", "a", "result,", "we", "recognized", "approximately", "$2.48", "million", "as", "a", "non-cash", "deemed", "dividend.", "<tag3>"], "wordsA": ["Additionally,", "we", "recognized", "approximately", "$8,000", "as", "payment", "for", "20%", "of", "Azanta", "s", "gross", "margin,", "as", "defined", "in", "the", "agreement,", "on", "its", "sales", "in", "the", "preceding", "quarter,", "in", "2012,", "after", "Azanta", "notified", "us", "of", "the", "amount."], "wordsB": ["The", "Series", "A", "Preferred", "Stock", "contained", "a", "beneficial", "conversion", "feature", "and,", "as", "a", "result,", "we", "recognized", "approximately", "$2.48", "million", "as", "a", "non-cash", "deemed", "dividend."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item7_p25_s0", "idA": "908259_13_item7_p14_s0", "sentA": "on our most promising early-stage clinical programs.", "sentB": "Investment income primarily reflects increases and decrease in cash balances due to interest earned on our operating cash accounts.", "type": 1, "words": ["<tag1>", "on", "our", "most", "promising", "early-stage", "clinical", "programs.", "<tag2>", "Investment", "income", "primarily", "reflects", "increases", "and", "decrease", "in", "cash", "balances", "due", "to", "interest", "earned", "on", "our", "operating", "cash", "accounts.", "<tag3>"], "wordsA": ["on", "our", "most", "promising", "early-stage", "clinical", "programs."], "wordsB": ["Investment", "income", "primarily", "reflects", "increases", "and", "decrease", "in", "cash", "balances", "due", "to", "interest", "earned", "on", "our", "operating", "cash", "accounts."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item7_p15_s1", "idA": "908259_13_item7_p18_s12", "sentA": "The restructuring is complete and the expenses in 2012 are reflective of the reductions in expense as a result of the restructuring.", "sentB": "The Series A Warrants and Series B Warrants granted were valued using the Black-Scholes valuation model and the following Level 3 input assumptions:", "type": 1, "words": ["<tag1>", "The", "restructuring", "is", "complete", "and", "the", "expenses", "in", "2012", "are", "reflective", "of", "the", "reductions", "in", "expense", "as", "a", "result", "of", "the", "restructuring.", "<tag2>", "The", "Series", "A", "Warrants", "and", "Series", "B", "Warrants", "granted", "were", "valued", "using", "the", "Black-Scholes", "valuation", "model", "and", "the", "following", "Level", "3", "input", "assumptions:", "<tag3>"], "wordsA": ["The", "restructuring", "is", "complete", "and", "the", "expenses", "in", "2012", "are", "reflective", "of", "the", "reductions", "in", "expense", "as", "a", "result", "of", "the", "restructuring."], "wordsB": ["The", "Series", "A", "Warrants", "and", "Series", "B", "Warrants", "granted", "were", "valued", "using", "the", "Black-Scholes", "valuation", "model", "and", "the", "following", "Level", "3", "input", "assumptions:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item7_p21_s8", "idA": "908259_13_item7_p1_s2", "sentA": "We have 3 product candidates in the development stage in three areas; ZYBRESTAT in oncology, OXi4503 in oncology and ZYBRESTAT in ophthalmology.", "sentB": "We have initiated and may continue to incur costs for drug manufacturing activities associated with the potential EMA filing for a European Marketing Authorization application for ZYBRESTAT in ATC.", "type": 1, "words": ["<tag1>", "We", "have", "3", "product", "candidates", "in", "the", "development", "stage", "in", "three", "areas;", "ZYBRESTAT", "in", "oncology,", "OXi4503", "in", "oncology", "and", "ZYBRESTAT", "in", "ophthalmology.", "<tag2>", "We", "have", "initiated", "and", "may", "continue", "to", "incur", "costs", "for", "drug", "manufacturing", "activities", "associated", "with", "the", "potential", "EMA", "filing", "for", "a", "European", "Marketing", "Authorization", "application", "for", "ZYBRESTAT", "in", "ATC.", "<tag3>"], "wordsA": ["We", "have", "3", "product", "candidates", "in", "the", "development", "stage", "in", "three", "areas;", "ZYBRESTAT", "in", "oncology,", "OXi4503", "in", "oncology", "and", "ZYBRESTAT", "in", "ophthalmology."], "wordsB": ["We", "have", "initiated", "and", "may", "continue", "to", "incur", "costs", "for", "drug", "manufacturing", "activities", "associated", "with", "the", "potential", "EMA", "filing", "for", "a", "European", "Marketing", "Authorization", "application", "for", "ZYBRESTAT", "in", "ATC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item7_p33_s4", "idA": "908259_13_item7_p21_s0", "sentA": "The table below summarizes the components of the change in fair value of warrants for the periods indicated, in thousands:", "sentB": "On September 23, 2013, we also agreed to redeem the remaining outstanding balance of the Series A Preferred Stock of 2,802 shares which had a redemption value of approximately $2,802,000.", "type": 1, "words": ["<tag1>", "The", "table", "below", "summarizes", "the", "components", "of", "the", "change", "in", "fair", "value", "of", "warrants", "for", "the", "periods", "indicated,", "in", "thousands:", "<tag2>", "On", "September", "23,", "2013,", "we", "also", "agreed", "to", "redeem", "the", "remaining", "outstanding", "balance", "of", "the", "Series", "A", "Preferred", "Stock", "of", "2,802", "shares", "which", "had", "a", "redemption", "value", "of", "approximately", "$2,802,000.", "<tag3>"], "wordsA": ["The", "table", "below", "summarizes", "the", "components", "of", "the", "change", "in", "fair", "value", "of", "warrants", "for", "the", "periods", "indicated,", "in", "thousands:"], "wordsB": ["On", "September", "23,", "2013,", "we", "also", "agreed", "to", "redeem", "the", "remaining", "outstanding", "balance", "of", "the", "Series", "A", "Preferred", "Stock", "of", "2,802", "shares", "which", "had", "a", "redemption", "value", "of", "approximately", "$2,802,000."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item7_p36_s5", "idA": "908259_13_item7_p23_s4", "sentA": "We had cash and restricted cash of approximately $4,966,000 at December 31, 2012.", "sentB": "Investors purchased an aggregate of approximately $12 million of units, in a registered public offering, at a price per unit of $2.05.", "type": 1, "words": ["<tag1>", "We", "had", "cash", "and", "restricted", "cash", "of", "approximately", "$4,966,000", "at", "December", "31,", "2012.", "<tag2>", "Investors", "purchased", "an", "aggregate", "of", "approximately", "$12", "million", "of", "units,", "in", "a", "registered", "public", "offering,", "at", "a", "price", "per", "unit", "of", "$2.05.", "<tag3>"], "wordsA": ["We", "had", "cash", "and", "restricted", "cash", "of", "approximately", "$4,966,000", "at", "December", "31,", "2012."], "wordsB": ["Investors", "purchased", "an", "aggregate", "of", "approximately", "$12", "million", "of", "units,", "in", "a", "registered", "public", "offering,", "at", "a", "price", "per", "unit", "of", "$2.05."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item7_p33_s1", "idA": "908259_13_item7_p24_s5", "sentA": "Net cash provided by financing activities for the year ended December 31, 2011 is primarily attributable to the net proceeds from the sale of common stock pursuant to the ATM Agreement discussed below.", "sentB": "After deducting costs associated with the offering, the net proceeds of this offering were approximately $4,192,000.", "type": 1, "words": ["<tag1>", "Net", "cash", "provided", "by", "financing", "activities", "for", "the", "year", "ended", "December", "31,", "2011", "is", "primarily", "attributable", "to", "the", "net", "proceeds", "from", "the", "sale", "of", "common", "stock", "pursuant", "to", "the", "ATM", "Agreement", "discussed", "below.", "<tag2>", "After", "deducting", "costs", "associated", "with", "the", "offering,", "the", "net", "proceeds", "of", "this", "offering", "were", "approximately", "$4,192,000.", "<tag3>"], "wordsA": ["Net", "cash", "provided", "by", "financing", "activities", "for", "the", "year", "ended", "December", "31,", "2011", "is", "primarily", "attributable", "to", "the", "net", "proceeds", "from", "the", "sale", "of", "common", "stock", "pursuant", "to", "the", "ATM", "Agreement", "discussed", "below."], "wordsB": ["After", "deducting", "costs", "associated", "with", "the", "offering,", "the", "net", "proceeds", "of", "this", "offering", "were", "approximately", "$4,192,000."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item7_p14_s0", "idA": "908259_13_item7_p25_s0", "sentA": "On January 18, 2011, we entered into separate Warrant Exchange Agreements with each of the holders of warrants to purchase shares of our common stock issued in March 2010, pursuant to which, at the initial closing, the warrant holders exchanged their outstanding Series A and Series C warrants having ratchet price-based anti-dilution protections for (A) an aggregate of 91,411 shares of common stock and (B) Series E Warrants to purchase an aggregate of 101,885 shares of common stock.", "sentB": "Valuation of preferred stock and warrants In April 2013, we issued Series A Preferred Stock, Series A Warrants and Series B Warrants in a private placement.", "type": 1, "words": ["<tag1>", "On", "January", "18,", "2011,", "we", "entered", "into", "separate", "Warrant", "Exchange", "Agreements", "with", "each", "of", "the", "holders", "of", "warrants", "to", "purchase", "shares", "of", "our", "common", "stock", "issued", "in", "March", "2010,", "pursuant", "to", "which,", "at", "the", "initial", "closing,", "the", "warrant", "holders", "exchanged", "their", "outstanding", "Series", "A", "and", "Series", "C", "warrants", "having", "ratchet", "price-based", "anti-dilution", "protections", "for", "(A)", "an", "aggregate", "of", "91,411", "shares", "of", "common", "stock", "and", "(B)", "Series", "E", "Warrants", "to", "purchase", "an", "aggregate", "of", "101,885", "shares", "of", "common", "stock.", "<tag2>", "Valuation", "of", "preferred", "stock", "and", "warrants", "In", "April", "2013,", "we", "issued", "Series", "A", "Preferred", "Stock,", "Series", "A", "Warrants", "and", "Series", "B", "Warrants", "in", "a", "private", "placement.", "<tag3>"], "wordsA": ["On", "January", "18,", "2011,", "we", "entered", "into", "separate", "Warrant", "Exchange", "Agreements", "with", "each", "of", "the", "holders", "of", "warrants", "to", "purchase", "shares", "of", "our", "common", "stock", "issued", "in", "March", "2010,", "pursuant", "to", "which,", "at", "the", "initial", "closing,", "the", "warrant", "holders", "exchanged", "their", "outstanding", "Series", "A", "and", "Series", "C", "warrants", "having", "ratchet", "price-based", "anti-dilution", "protections", "for", "(A)", "an", "aggregate", "of", "91,411", "shares", "of", "common", "stock", "and", "(B)", "Series", "E", "Warrants", "to", "purchase", "an", "aggregate", "of", "101,885", "shares", "of", "common", "stock."], "wordsB": ["Valuation", "of", "preferred", "stock", "and", "warrants", "In", "April", "2013,", "we", "issued", "Series", "A", "Preferred", "Stock,", "Series", "A", "Warrants", "and", "Series", "B", "Warrants", "in", "a", "private", "placement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item7_p36_s1", "idA": "908259_13_item7_p25_s0", "sentA": "On January 18, 2011, we entered into separate Warrant Exchange Agreements with each of the holders of warrants to purchase shares of our common stock issued in March 2010, pursuant to which, at the initial closing, the warrant holders exchanged their outstanding Series A and Series C warrants having ratchet price-based anti-dilution protections for (A) an aggregate of 91,411 shares of common stock and (B) Series E Warrants to purchase an aggregate of 101,885 shares of common stock.", "sentB": "We used the proceeds of the September 2013 offering in part to redeem the outstanding shares of Series A Preferred Stock issued in April 2013 (see above).", "type": 1, "words": ["<tag1>", "On", "January", "18,", "2011,", "we", "entered", "into", "separate", "Warrant", "Exchange", "Agreements", "with", "each", "of", "the", "holders", "of", "warrants", "to", "purchase", "shares", "of", "our", "common", "stock", "issued", "in", "March", "2010,", "pursuant", "to", "which,", "at", "the", "initial", "closing,", "the", "warrant", "holders", "exchanged", "their", "outstanding", "Series", "A", "and", "Series", "C", "warrants", "having", "ratchet", "price-based", "anti-dilution", "protections", "for", "(A)", "an", "aggregate", "of", "91,411", "shares", "of", "common", "stock", "and", "(B)", "Series", "E", "Warrants", "to", "purchase", "an", "aggregate", "of", "101,885", "shares", "of", "common", "stock.", "<tag2>", "We", "used", "the", "proceeds", "of", "the", "September", "2013", "offering", "in", "part", "to", "redeem", "the", "outstanding", "shares", "of", "Series", "A", "Preferred", "Stock", "issued", "in", "April", "2013", "(see", "above).", "<tag3>"], "wordsA": ["On", "January", "18,", "2011,", "we", "entered", "into", "separate", "Warrant", "Exchange", "Agreements", "with", "each", "of", "the", "holders", "of", "warrants", "to", "purchase", "shares", "of", "our", "common", "stock", "issued", "in", "March", "2010,", "pursuant", "to", "which,", "at", "the", "initial", "closing,", "the", "warrant", "holders", "exchanged", "their", "outstanding", "Series", "A", "and", "Series", "C", "warrants", "having", "ratchet", "price-based", "anti-dilution", "protections", "for", "(A)", "an", "aggregate", "of", "91,411", "shares", "of", "common", "stock", "and", "(B)", "Series", "E", "Warrants", "to", "purchase", "an", "aggregate", "of", "101,885", "shares", "of", "common", "stock."], "wordsB": ["We", "used", "the", "proceeds", "of", "the", "September", "2013", "offering", "in", "part", "to", "redeem", "the", "outstanding", "shares", "of", "Series", "A", "Preferred", "Stock", "issued", "in", "April", "2013", "(see", "above)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item7_p32_s1", "idA": "908259_13_item7_p25_s1", "sentA": "The Series E Warrants were not exercisable for six months, had an exercise price of $55.20 per share (reflecting the market value of the shares of common stock as of the close of trading on January 18, 2011, prior to the entry into the Warrant Exchange Agreements), and did not contain any price-based anti-dilution protections.", "sentB": "The Series A Preferred Stock was not redeemable or contingently redeemable, did not have a dividend right, nor did it have any preferences over our common stock, including liquidation rights.", "type": 1, "words": ["<tag1>", "The", "Series", "E", "Warrants", "were", "not", "exercisable", "for", "six", "months,", "had", "an", "exercise", "price", "of", "$55.20", "per", "share", "(reflecting", "the", "market", "value", "of", "the", "shares", "of", "common", "stock", "as", "of", "the", "close", "of", "trading", "on", "January", "18,", "2011,", "prior", "to", "the", "entry", "into", "the", "Warrant", "Exchange", "Agreements),", "and", "did", "not", "contain", "any", "price-based", "anti-dilution", "protections.", "<tag2>", "The", "Series", "A", "Preferred", "Stock", "was", "not", "redeemable", "or", "contingently", "redeemable,", "did", "not", "have", "a", "dividend", "right,", "nor", "did", "it", "have", "any", "preferences", "over", "our", "common", "stock,", "including", "liquidation", "rights.", "<tag3>"], "wordsA": ["The", "Series", "E", "Warrants", "were", "not", "exercisable", "for", "six", "months,", "had", "an", "exercise", "price", "of", "$55.20", "per", "share", "(reflecting", "the", "market", "value", "of", "the", "shares", "of", "common", "stock", "as", "of", "the", "close", "of", "trading", "on", "January", "18,", "2011,", "prior", "to", "the", "entry", "into", "the", "Warrant", "Exchange", "Agreements),", "and", "did", "not", "contain", "any", "price-based", "anti-dilution", "protections."], "wordsB": ["The", "Series", "A", "Preferred", "Stock", "was", "not", "redeemable", "or", "contingently", "redeemable,", "did", "not", "have", "a", "dividend", "right,", "nor", "did", "it", "have", "any", "preferences", "over", "our", "common", "stock,", "including", "liquidation", "rights."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item7_p34_s1", "idA": "908259_13_item7_p25_s1", "sentA": "The Series E Warrants were not exercisable for six months, had an exercise price of $55.20 per share (reflecting the market value of the shares of common stock as of the close of trading on January 18, 2011, prior to the entry into the Warrant Exchange Agreements), and did not contain any price-based anti-dilution protections.", "sentB": "The Series B Preferred Stock was not redeemable or contingently redeemable, did not have a dividend right, nor did it have any preferences over the common stock, including liquidation rights.", "type": 1, "words": ["<tag1>", "The", "Series", "E", "Warrants", "were", "not", "exercisable", "for", "six", "months,", "had", "an", "exercise", "price", "of", "$55.20", "per", "share", "(reflecting", "the", "market", "value", "of", "the", "shares", "of", "common", "stock", "as", "of", "the", "close", "of", "trading", "on", "January", "18,", "2011,", "prior", "to", "the", "entry", "into", "the", "Warrant", "Exchange", "Agreements),", "and", "did", "not", "contain", "any", "price-based", "anti-dilution", "protections.", "<tag2>", "The", "Series", "B", "Preferred", "Stock", "was", "not", "redeemable", "or", "contingently", "redeemable,", "did", "not", "have", "a", "dividend", "right,", "nor", "did", "it", "have", "any", "preferences", "over", "the", "common", "stock,", "including", "liquidation", "rights.", "<tag3>"], "wordsA": ["The", "Series", "E", "Warrants", "were", "not", "exercisable", "for", "six", "months,", "had", "an", "exercise", "price", "of", "$55.20", "per", "share", "(reflecting", "the", "market", "value", "of", "the", "shares", "of", "common", "stock", "as", "of", "the", "close", "of", "trading", "on", "January", "18,", "2011,", "prior", "to", "the", "entry", "into", "the", "Warrant", "Exchange", "Agreements),", "and", "did", "not", "contain", "any", "price-based", "anti-dilution", "protections."], "wordsB": ["The", "Series", "B", "Preferred", "Stock", "was", "not", "redeemable", "or", "contingently", "redeemable,", "did", "not", "have", "a", "dividend", "right,", "nor", "did", "it", "have", "any", "preferences", "over", "the", "common", "stock,", "including", "liquidation", "rights."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item7_p31_s0", "idA": "908259_13_item7_p25_s2", "sentA": "In addition, we agreed to seek shareholder approval to issue up to 38,128 additional shares of common stock to the warrant holders in a subsequent closing.", "sentB": "On April 16, 2013, we closed an offering pursuant to the terms of a private placement agreement, in which we raised $5,000,000 in gross proceeds, before deducting placement agents fees and other offering expenses, in a private placement of 5,000 shares of our Series A Preferred Stock.", "type": 1, "words": ["<tag1>", "In", "addition,", "we", "agreed", "to", "seek", "shareholder", "approval", "to", "issue", "up", "to", "38,128", "additional", "shares", "of", "common", "stock", "to", "the", "warrant", "holders", "in", "a", "subsequent", "closing.", "<tag2>", "On", "April", "16,", "2013,", "we", "closed", "an", "offering", "pursuant", "to", "the", "terms", "of", "a", "private", "placement", "agreement,", "in", "which", "we", "raised", "$5,000,000", "in", "gross", "proceeds,", "before", "deducting", "placement", "agents", "fees", "and", "other", "offering", "expenses,", "in", "a", "private", "placement", "of", "5,000", "shares", "of", "our", "Series", "A", "Preferred", "Stock.", "<tag3>"], "wordsA": ["In", "addition,", "we", "agreed", "to", "seek", "shareholder", "approval", "to", "issue", "up", "to", "38,128", "additional", "shares", "of", "common", "stock", "to", "the", "warrant", "holders", "in", "a", "subsequent", "closing."], "wordsB": ["On", "April", "16,", "2013,", "we", "closed", "an", "offering", "pursuant", "to", "the", "terms", "of", "a", "private", "placement", "agreement,", "in", "which", "we", "raised", "$5,000,000", "in", "gross", "proceeds,", "before", "deducting", "placement", "agents", "fees", "and", "other", "offering", "expenses,", "in", "a", "private", "placement", "of", "5,000", "shares", "of", "our", "Series", "A", "Preferred", "Stock."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item7_p33_s3", "idA": "908259_13_item7_p25_s2", "sentA": "In addition, we agreed to seek shareholder approval to issue up to 38,128 additional shares of common stock to the warrant holders in a subsequent closing.", "sentB": "On September 23, 2013, we closed on another offering pursuant to the terms of a private placement agreement, in which we raised $5,800,000 in gross proceeds, before deducting placement agents fees and other offering expenses, in a private placement of 5,800 shares of our Series B Preferred Stock.", "type": 1, "words": ["<tag1>", "In", "addition,", "we", "agreed", "to", "seek", "shareholder", "approval", "to", "issue", "up", "to", "38,128", "additional", "shares", "of", "common", "stock", "to", "the", "warrant", "holders", "in", "a", "subsequent", "closing.", "<tag2>", "On", "September", "23,", "2013,", "we", "closed", "on", "another", "offering", "pursuant", "to", "the", "terms", "of", "a", "private", "placement", "agreement,", "in", "which", "we", "raised", "$5,800,000", "in", "gross", "proceeds,", "before", "deducting", "placement", "agents", "fees", "and", "other", "offering", "expenses,", "in", "a", "private", "placement", "of", "5,800", "shares", "of", "our", "Series", "B", "Preferred", "Stock.", "<tag3>"], "wordsA": ["In", "addition,", "we", "agreed", "to", "seek", "shareholder", "approval", "to", "issue", "up", "to", "38,128", "additional", "shares", "of", "common", "stock", "to", "the", "warrant", "holders", "in", "a", "subsequent", "closing."], "wordsB": ["On", "September", "23,", "2013,", "we", "closed", "on", "another", "offering", "pursuant", "to", "the", "terms", "of", "a", "private", "placement", "agreement,", "in", "which", "we", "raised", "$5,800,000", "in", "gross", "proceeds,", "before", "deducting", "placement", "agents", "fees", "and", "other", "offering", "expenses,", "in", "a", "private", "placement", "of", "5,800", "shares", "of", "our", "Series", "B", "Preferred", "Stock."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item7_p15_s7", "idA": "908259_13_item7_p25_s3", "sentA": "Such shareholder approval was obtained on March 18, 2011, and the Series E Warrants issued at the initial closing were exchanged for the additional 38,128 shares of common stock.", "sentB": "The fair values for the Warrants granted were valued using the Black-Scholes valuation model and the following Level 3 input assumptions:", "type": 1, "words": ["<tag1>", "Such", "shareholder", "approval", "was", "obtained", "on", "March", "18,", "2011,", "and", "the", "Series", "E", "Warrants", "issued", "at", "the", "initial", "closing", "were", "exchanged", "for", "the", "additional", "38,128", "shares", "of", "common", "stock.", "<tag2>", "The", "fair", "values", "for", "the", "Warrants", "granted", "were", "valued", "using", "the", "Black-Scholes", "valuation", "model", "and", "the", "following", "Level", "3", "input", "assumptions:", "<tag3>"], "wordsA": ["Such", "shareholder", "approval", "was", "obtained", "on", "March", "18,", "2011,", "and", "the", "Series", "E", "Warrants", "issued", "at", "the", "initial", "closing", "were", "exchanged", "for", "the", "additional", "38,128", "shares", "of", "common", "stock."], "wordsB": ["The", "fair", "values", "for", "the", "Warrants", "granted", "were", "valued", "using", "the", "Black-Scholes", "valuation", "model", "and", "the", "following", "Level", "3", "input", "assumptions:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item7_p21_s9", "idA": "908259_13_item7_p34_s3", "sentA": "The agreement provides for additional payments in connection with the license arrangement upon the initiation of certain clinical trials or the completion of certain regulatory approvals, which payments could be accelerated upon the achievement of certain financial milestones, as defined in the agreement.", "sentB": "Additionally, we expect to incur costs associated with the initiation of our Phase 2 trial of ZYBRESTAT in patients with recurrent GI-NETs with elevated biomarkers, and, if we finalize an agreement with a non-profit collaborator, we expect to share in the costs of initiating a Phase 1b/2 trial of ZYBRESTAT in relapsed ovarian cancer in combination with Votrient .", "type": 1, "words": ["<tag1>", "The", "agreement", "provides", "for", "additional", "payments", "in", "connection", "with", "the", "license", "arrangement", "upon", "the", "initiation", "of", "certain", "clinical", "trials", "or", "the", "completion", "of", "certain", "regulatory", "approvals,", "which", "payments", "could", "be", "accelerated", "upon", "the", "achievement", "of", "certain", "financial", "milestones,", "as", "defined", "in", "the", "agreement.", "<tag2>", "Additionally,", "we", "expect", "to", "incur", "costs", "associated", "with", "the", "initiation", "of", "our", "Phase", "2", "trial", "of", "ZYBRESTAT", "in", "patients", "with", "recurrent", "GI-NETs", "with", "elevated", "biomarkers,", "and,", "if", "we", "finalize", "an", "agreement", "with", "a", "non-profit", "collaborator,", "we", "expect", "to", "share", "in", "the", "costs", "of", "initiating", "a", "Phase", "1b/2", "trial", "of", "ZYBRESTAT", "in", "relapsed", "ovarian", "cancer", "in", "combination", "with", "Votrient", ".", "<tag3>"], "wordsA": ["The", "agreement", "provides", "for", "additional", "payments", "in", "connection", "with", "the", "license", "arrangement", "upon", "the", "initiation", "of", "certain", "clinical", "trials", "or", "the", "completion", "of", "certain", "regulatory", "approvals,", "which", "payments", "could", "be", "accelerated", "upon", "the", "achievement", "of", "certain", "financial", "milestones,", "as", "defined", "in", "the", "agreement."], "wordsB": ["Additionally,", "we", "expect", "to", "incur", "costs", "associated", "with", "the", "initiation", "of", "our", "Phase", "2", "trial", "of", "ZYBRESTAT", "in", "patients", "with", "recurrent", "GI-NETs", "with", "elevated", "biomarkers,", "and,", "if", "we", "finalize", "an", "agreement", "with", "a", "non-profit", "collaborator,", "we", "expect", "to", "share", "in", "the", "costs", "of", "initiating", "a", "Phase", "1b/2", "trial", "of", "ZYBRESTAT", "in", "relapsed", "ovarian", "cancer", "in", "combination", "with", "Votrient", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item7_p36_s4", "idA": "908259_13_item7_p5_s7", "sentA": "We also have entered into an at the market equity offering sales agreement, or the ATM Agreement, with MLV Co. LLC, or MLV, pursuant to which we may issue and sell shares of common stock from time to time through MLV acting as our sales agent and underwriter.", "sentB": "On February 18, 2014, we closed on a public offering of common stock and warrants, in which we raised approximately $11,106,000 in net proceeds, after deducting placement agents fees, and before other offering expenses.", "type": 1, "words": ["<tag1>", "We", "also", "have", "entered", "into", "an", "at", "the", "market", "equity", "offering", "sales", "agreement,", "or", "the", "ATM", "Agreement,", "with", "MLV", "Co.", "LLC,", "or", "MLV,", "pursuant", "to", "which", "we", "may", "issue", "and", "sell", "shares", "of", "common", "stock", "from", "time", "to", "time", "through", "MLV", "acting", "as", "our", "sales", "agent", "and", "underwriter.", "<tag2>", "On", "February", "18,", "2014,", "we", "closed", "on", "a", "public", "offering", "of", "common", "stock", "and", "warrants,", "in", "which", "we", "raised", "approximately", "$11,106,000", "in", "net", "proceeds,", "after", "deducting", "placement", "agents", "fees,", "and", "before", "other", "offering", "expenses.", "<tag3>"], "wordsA": ["We", "also", "have", "entered", "into", "an", "at", "the", "market", "equity", "offering", "sales", "agreement,", "or", "the", "ATM", "Agreement,", "with", "MLV", "Co.", "LLC,", "or", "MLV,", "pursuant", "to", "which", "we", "may", "issue", "and", "sell", "shares", "of", "common", "stock", "from", "time", "to", "time", "through", "MLV", "acting", "as", "our", "sales", "agent", "and", "underwriter."], "wordsB": ["On", "February", "18,", "2014,", "we", "closed", "on", "a", "public", "offering", "of", "common", "stock", "and", "warrants,", "in", "which", "we", "raised", "approximately", "$11,106,000", "in", "net", "proceeds,", "after", "deducting", "placement", "agents", "fees,", "and", "before", "other", "offering", "expenses."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item7_p1_s2", "idA": "908259_14_item7_p21_s9", "sentA": "Additionally, we expect to incur costs associated with the initiation of our Phase 2 trial of ZYBRESTAT in patients with recurrent GI-NETs with elevated biomarkers, and, if we finalize an agreement with a non-profit collaborator, we expect to share in the costs of initiating a Phase 1b/2 trial of ZYBRESTAT in relapsed ovarian cancer in combination with Votrient .", "sentB": "Our lead compound, fosbretabulin, is currently being tested in two indications, recurrent ovarian cancer and gastrointestinal neuroendocrine tumors, or GI-NETs, and our second compound, OXi4503, is currently being tested in patients with relapsed or refractory acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS).", "type": 1, "words": ["<tag1>", "Additionally,", "we", "expect", "to", "incur", "costs", "associated", "with", "the", "initiation", "of", "our", "Phase", "2", "trial", "of", "ZYBRESTAT", "in", "patients", "with", "recurrent", "GI-NETs", "with", "elevated", "biomarkers,", "and,", "if", "we", "finalize", "an", "agreement", "with", "a", "non-profit", "collaborator,", "we", "expect", "to", "share", "in", "the", "costs", "of", "initiating", "a", "Phase", "1b/2", "trial", "of", "ZYBRESTAT", "in", "relapsed", "ovarian", "cancer", "in", "combination", "with", "Votrient", ".", "<tag2>", "Our", "lead", "compound,", "fosbretabulin,", "is", "currently", "being", "tested", "in", "two", "indications,", "recurrent", "ovarian", "cancer", "and", "gastrointestinal", "neuroendocrine", "tumors,", "or", "GI-NETs,", "and", "our", "second", "compound,", "OXi4503,", "is", "currently", "being", "tested", "in", "patients", "with", "relapsed", "or", "refractory", "acute", "myelogenous", "leukemia", "(AML)", "or", "myelodysplastic", "syndromes", "(MDS).", "<tag3>"], "wordsA": ["Additionally,", "we", "expect", "to", "incur", "costs", "associated", "with", "the", "initiation", "of", "our", "Phase", "2", "trial", "of", "ZYBRESTAT", "in", "patients", "with", "recurrent", "GI-NETs", "with", "elevated", "biomarkers,", "and,", "if", "we", "finalize", "an", "agreement", "with", "a", "non-profit", "collaborator,", "we", "expect", "to", "share", "in", "the", "costs", "of", "initiating", "a", "Phase", "1b/2", "trial", "of", "ZYBRESTAT", "in", "relapsed", "ovarian", "cancer", "in", "combination", "with", "Votrient", "."], "wordsB": ["Our", "lead", "compound,", "fosbretabulin,", "is", "currently", "being", "tested", "in", "two", "indications,", "recurrent", "ovarian", "cancer", "and", "gastrointestinal", "neuroendocrine", "tumors,", "or", "GI-NETs,", "and", "our", "second", "compound,", "OXi4503,", "is", "currently", "being", "tested", "in", "patients", "with", "relapsed", "or", "refractory", "acute", "myelogenous", "leukemia", "(AML)", "or", "myelodysplastic", "syndromes", "(MDS)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item7_p3_s2", "idA": "908259_14_item7_p22_s11", "sentA": "As a result, general and administrative expenses in the future could vary significantly from those incurred in the 2013 fiscal year.", "sentB": "As a result, we explored the possibility with the European regulatory agencies regarding the potential to submit a special marketing approval, or MAA, in the European Union for ATC under the exceptional circumstances pathway, and while we received useful feedback, given our current priorities and resources, we decided in 2014 not to actively pursue such a filing at this time.", "type": 1, "words": ["<tag1>", "As", "a", "result,", "general", "and", "administrative", "expenses", "in", "the", "future", "could", "vary", "significantly", "from", "those", "incurred", "in", "the", "2013", "fiscal", "year.", "<tag2>", "As", "a", "result,", "we", "explored", "the", "possibility", "with", "the", "European", "regulatory", "agencies", "regarding", "the", "potential", "to", "submit", "a", "special", "marketing", "approval,", "or", "MAA,", "in", "the", "European", "Union", "for", "ATC", "under", "the", "exceptional", "circumstances", "pathway,", "and", "while", "we", "received", "useful", "feedback,", "given", "our", "current", "priorities", "and", "resources,", "we", "decided", "in", "2014", "not", "to", "actively", "pursue", "such", "a", "filing", "at", "this", "time.", "<tag3>"], "wordsA": ["As", "a", "result,", "general", "and", "administrative", "expenses", "in", "the", "future", "could", "vary", "significantly", "from", "those", "incurred", "in", "the", "2013", "fiscal", "year."], "wordsB": ["As", "a", "result,", "we", "explored", "the", "possibility", "with", "the", "European", "regulatory", "agencies", "regarding", "the", "potential", "to", "submit", "a", "special", "marketing", "approval,", "or", "MAA,", "in", "the", "European", "Union", "for", "ATC", "under", "the", "exceptional", "circumstances", "pathway,", "and", "while", "we", "received", "useful", "feedback,", "given", "our", "current", "priorities", "and", "resources,", "we", "decided", "in", "2014", "not", "to", "actively", "pursue", "such", "a", "filing", "at", "this", "time."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item7_p38_s9", "idA": "908259_14_item7_p41_s2", "sentA": "Under the terms of the agreement, we provide ZYBRESTAT to the Danish company.", "sentB": "None of the warrants issued on March 25, 2015 have been exercised.", "type": 1, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "provide", "ZYBRESTAT", "to", "the", "Danish", "company.", "<tag2>", "None", "of", "the", "warrants", "issued", "on", "March", "25,", "2015", "have", "been", "exercised.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "provide", "ZYBRESTAT", "to", "the", "Danish", "company."], "wordsB": ["None", "of", "the", "warrants", "issued", "on", "March", "25,", "2015", "have", "been", "exercised."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item7_p2_s1", "idA": "908259_15_item7_p0_s4", "sentA": "Further, we operate in an industry sector where securities prices are volatile and may be influenced by regulatory and other factors beyond our control.", "sentB": "Bevacizumab and other currently approved AA drugs work by preventing the growth of new blood vessels which can supply nutrients to tumor cells.", "type": 1, "words": ["<tag1>", "Further,", "we", "operate", "in", "an", "industry", "sector", "where", "securities", "prices", "are", "volatile", "and", "may", "be", "influenced", "by", "regulatory", "and", "other", "factors", "beyond", "our", "control.", "<tag2>", "Bevacizumab", "and", "other", "currently", "approved", "AA", "drugs", "work", "by", "preventing", "the", "growth", "of", "new", "blood", "vessels", "which", "can", "supply", "nutrients", "to", "tumor", "cells.", "<tag3>"], "wordsA": ["Further,", "we", "operate", "in", "an", "industry", "sector", "where", "securities", "prices", "are", "volatile", "and", "may", "be", "influenced", "by", "regulatory", "and", "other", "factors", "beyond", "our", "control."], "wordsB": ["Bevacizumab", "and", "other", "currently", "approved", "AA", "drugs", "work", "by", "preventing", "the", "growth", "of", "new", "blood", "vessels", "which", "can", "supply", "nutrients", "to", "tumor", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item7_p21_s1", "idA": "908259_15_item7_p16_s5", "sentA": "In order to calculate the amount of the deemed dividend, we calculated the amount of the consideration transferred to the holders of the Series B Preferred Stock which included the estimated value of the Series B Preferred Stock and Warrants.", "sentB": "Although our investments are subject to credit risk, we follow procedures to limit the amount of credit exposure in any single issue, issuer or type of investment.", "type": 1, "words": ["<tag1>", "In", "order", "to", "calculate", "the", "amount", "of", "the", "deemed", "dividend,", "we", "calculated", "the", "amount", "of", "the", "consideration", "transferred", "to", "the", "holders", "of", "the", "Series", "B", "Preferred", "Stock", "which", "included", "the", "estimated", "value", "of", "the", "Series", "B", "Preferred", "Stock", "and", "Warrants.", "<tag2>", "Although", "our", "investments", "are", "subject", "to", "credit", "risk,", "we", "follow", "procedures", "to", "limit", "the", "amount", "of", "credit", "exposure", "in", "any", "single", "issue,", "issuer", "or", "type", "of", "investment.", "<tag3>"], "wordsA": ["In", "order", "to", "calculate", "the", "amount", "of", "the", "deemed", "dividend,", "we", "calculated", "the", "amount", "of", "the", "consideration", "transferred", "to", "the", "holders", "of", "the", "Series", "B", "Preferred", "Stock", "which", "included", "the", "estimated", "value", "of", "the", "Series", "B", "Preferred", "Stock", "and", "Warrants."], "wordsB": ["Although", "our", "investments", "are", "subject", "to", "credit", "risk,", "we", "follow", "procedures", "to", "limit", "the", "amount", "of", "credit", "exposure", "in", "any", "single", "issue,", "issuer", "or", "type", "of", "investment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item7_p10_s3", "idA": "908259_15_item7_p18_s3", "sentA": "External services include manufacturing for our drug product for clinical use, manufacturing for our drug product required for regulatory filings, clinical research organizations, clinical site services, labs and other outside services.", "sentB": "Clinical studies expenses include fees paid to contract research organizations who conduct clinical trials on our behalf, patient and clinical site costs, laboratory costs and other services directly related to clinical trials.", "type": 1, "words": ["<tag1>", "External", "services", "include", "manufacturing", "for", "our", "drug", "product", "for", "clinical", "use,", "manufacturing", "for", "our", "drug", "product", "required", "for", "regulatory", "filings,", "clinical", "research", "organizations,", "clinical", "site", "services,", "labs", "and", "other", "outside", "services.", "<tag2>", "Clinical", "studies", "expenses", "include", "fees", "paid", "to", "contract", "research", "organizations", "who", "conduct", "clinical", "trials", "on", "our", "behalf,", "patient", "and", "clinical", "site", "costs,", "laboratory", "costs", "and", "other", "services", "directly", "related", "to", "clinical", "trials.", "<tag3>"], "wordsA": ["External", "services", "include", "manufacturing", "for", "our", "drug", "product", "for", "clinical", "use,", "manufacturing", "for", "our", "drug", "product", "required", "for", "regulatory", "filings,", "clinical", "research", "organizations,", "clinical", "site", "services,", "labs", "and", "other", "outside", "services."], "wordsB": ["Clinical", "studies", "expenses", "include", "fees", "paid", "to", "contract", "research", "organizations", "who", "conduct", "clinical", "trials", "on", "our", "behalf,", "patient", "and", "clinical", "site", "costs,", "laboratory", "costs", "and", "other", "services", "directly", "related", "to", "clinical", "trials."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item7_p2_s7", "idA": "908259_15_item7_p18_s6", "sentA": "To a lesser extent, the increase in external services is also due to our use of consultant services related to the evaluation of our ovarian cancer program and the results from the GOG-0186I Phase 2 clinical trial in ovarian cancer and planning related to our AML clinical program.", "sentB": "Based on the positive results of this clinical trial, we are initiating a phase 2/3 clinical trial in platinum-resistant ovarian cancer, which will compare treatment with CA4P, bevacizumab and chemotherapy to treatment with bevacizumab and chemotherapy.", "type": 1, "words": ["<tag1>", "To", "a", "lesser", "extent,", "the", "increase", "in", "external", "services", "is", "also", "due", "to", "our", "use", "of", "consultant", "services", "related", "to", "the", "evaluation", "of", "our", "ovarian", "cancer", "program", "and", "the", "results", "from", "the", "GOG-0186I", "Phase", "2", "clinical", "trial", "in", "ovarian", "cancer", "and", "planning", "related", "to", "our", "AML", "clinical", "program.", "<tag2>", "Based", "on", "the", "positive", "results", "of", "this", "clinical", "trial,", "we", "are", "initiating", "a", "phase", "2/3", "clinical", "trial", "in", "platinum-resistant", "ovarian", "cancer,", "which", "will", "compare", "treatment", "with", "CA4P,", "bevacizumab", "and", "chemotherapy", "to", "treatment", "with", "bevacizumab", "and", "chemotherapy.", "<tag3>"], "wordsA": ["To", "a", "lesser", "extent,", "the", "increase", "in", "external", "services", "is", "also", "due", "to", "our", "use", "of", "consultant", "services", "related", "to", "the", "evaluation", "of", "our", "ovarian", "cancer", "program", "and", "the", "results", "from", "the", "GOG-0186I", "Phase", "2", "clinical", "trial", "in", "ovarian", "cancer", "and", "planning", "related", "to", "our", "AML", "clinical", "program."], "wordsB": ["Based", "on", "the", "positive", "results", "of", "this", "clinical", "trial,", "we", "are", "initiating", "a", "phase", "2/3", "clinical", "trial", "in", "platinum-resistant", "ovarian", "cancer,", "which", "will", "compare", "treatment", "with", "CA4P,", "bevacizumab", "and", "chemotherapy", "to", "treatment", "with", "bevacizumab", "and", "chemotherapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item7_p1_s1", "idA": "908259_15_item7_p1_s0", "sentA": "We are a biopharmaceutical company primarily focused on the development of vascular disrupting agents, or VDAs, for the treatment of cancer.", "sentB": "VDAs selectively target the vasculature of cancer tumors and obstruct a tumor s blood supply without disrupting the blood supply to normal tissues.", "type": 1, "words": ["<tag1>", "We", "are", "a", "biopharmaceutical", "company", "primarily", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer.", "<tag2>", "VDAs", "selectively", "target", "the", "vasculature", "of", "cancer", "tumors", "and", "obstruct", "a", "tumor", "s", "blood", "supply", "without", "disrupting", "the", "blood", "supply", "to", "normal", "tissues.", "<tag3>"], "wordsA": ["We", "are", "a", "biopharmaceutical", "company", "primarily", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer."], "wordsB": ["VDAs", "selectively", "target", "the", "vasculature", "of", "cancer", "tumors", "and", "obstruct", "a", "tumor", "s", "blood", "supply", "without", "disrupting", "the", "blood", "supply", "to", "normal", "tissues."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item7_p2_s0", "idA": "908259_15_item7_p1_s0", "sentA": "We are a biopharmaceutical company primarily focused on the development of vascular disrupting agents, or VDAs, for the treatment of cancer.", "sentB": "VDAs are in a class of drugs called vascular targeted therapies, or VTTs, which also includes anti-angiogenic agents, or AAs.", "type": 1, "words": ["<tag1>", "We", "are", "a", "biopharmaceutical", "company", "primarily", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer.", "<tag2>", "VDAs", "are", "in", "a", "class", "of", "drugs", "called", "vascular", "targeted", "therapies,", "or", "VTTs,", "which", "also", "includes", "anti-angiogenic", "agents,", "or", "AAs.", "<tag3>"], "wordsA": ["We", "are", "a", "biopharmaceutical", "company", "primarily", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer."], "wordsB": ["VDAs", "are", "in", "a", "class", "of", "drugs", "called", "vascular", "targeted", "therapies,", "or", "VTTs,", "which", "also", "includes", "anti-angiogenic", "agents,", "or", "AAs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item7_p21_s0", "idA": "908259_15_item7_p1_s1", "sentA": "We have two clinical stage product candidates that we are currently developing in three potential oncology indications.", "sentB": "I TEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK We have adopted an Investment Policy, the primary objectives of which are to preserve principal, maintain proper liquidity to meet operating needs and maximize yields while preserving principal.", "type": 1, "words": ["<tag1>", "We", "have", "two", "clinical", "stage", "product", "candidates", "that", "we", "are", "currently", "developing", "in", "three", "potential", "oncology", "indications.", "<tag2>", "I", "TEM", "7A.", "QUANTITATIVE", "AND", "QUALITATIVE", "DISCLOSURES", "ABOUT", "MARKET", "RISK", "We", "have", "adopted", "an", "Investment", "Policy,", "the", "primary", "objectives", "of", "which", "are", "to", "preserve", "principal,", "maintain", "proper", "liquidity", "to", "meet", "operating", "needs", "and", "maximize", "yields", "while", "preserving", "principal.", "<tag3>"], "wordsA": ["We", "have", "two", "clinical", "stage", "product", "candidates", "that", "we", "are", "currently", "developing", "in", "three", "potential", "oncology", "indications."], "wordsB": ["I", "TEM", "7A.", "QUANTITATIVE", "AND", "QUALITATIVE", "DISCLOSURES", "ABOUT", "MARKET", "RISK", "We", "have", "adopted", "an", "Investment", "Policy,", "the", "primary", "objectives", "of", "which", "are", "to", "preserve", "principal,", "maintain", "proper", "liquidity", "to", "meet", "operating", "needs", "and", "maximize", "yields", "while", "preserving", "principal."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item7_p2_s2", "idA": "908259_15_item7_p1_s5", "sentA": "We are pursuing what we believe to be a cost-efficient, risk-mitigated development strategy.", "sentB": "We are seeking to realize the full potential of VTTs in oncology by using the combination of VDAs and AAs to treat cancer tumors.", "type": 1, "words": ["<tag1>", "We", "are", "pursuing", "what", "we", "believe", "to", "be", "a", "cost-efficient,", "risk-mitigated", "development", "strategy.", "<tag2>", "We", "are", "seeking", "to", "realize", "the", "full", "potential", "of", "VTTs", "in", "oncology", "by", "using", "the", "combination", "of", "VDAs", "and", "AAs", "to", "treat", "cancer", "tumors.", "<tag3>"], "wordsA": ["We", "are", "pursuing", "what", "we", "believe", "to", "be", "a", "cost-efficient,", "risk-mitigated", "development", "strategy."], "wordsB": ["We", "are", "seeking", "to", "realize", "the", "full", "potential", "of", "VTTs", "in", "oncology", "by", "using", "the", "combination", "of", "VDAs", "and", "AAs", "to", "treat", "cancer", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item7_p5_s10", "idA": "908259_15_item7_p1_s8", "sentA": "We also continued to support our Phase 1 clinical trial testing OXi4503 in AML, being conducted by the University of Florida, and our distribution agreement for the compassionate use of fosbretabulin in ATC (which was terminated effective December 31, 2014).", "sentB": "Based on patient enrollment reports and services provided, we may periodically adjust estimates for the clinical trial costs.", "type": 1, "words": ["<tag1>", "We", "also", "continued", "to", "support", "our", "Phase", "1", "clinical", "trial", "testing", "OXi4503", "in", "AML,", "being", "conducted", "by", "the", "University", "of", "Florida,", "and", "our", "distribution", "agreement", "for", "the", "compassionate", "use", "of", "fosbretabulin", "in", "ATC", "(which", "was", "terminated", "effective", "December", "31,", "2014).", "<tag2>", "Based", "on", "patient", "enrollment", "reports", "and", "services", "provided,", "we", "may", "periodically", "adjust", "estimates", "for", "the", "clinical", "trial", "costs.", "<tag3>"], "wordsA": ["We", "also", "continued", "to", "support", "our", "Phase", "1", "clinical", "trial", "testing", "OXi4503", "in", "AML,", "being", "conducted", "by", "the", "University", "of", "Florida,", "and", "our", "distribution", "agreement", "for", "the", "compassionate", "use", "of", "fosbretabulin", "in", "ATC", "(which", "was", "terminated", "effective", "December", "31,", "2014)."], "wordsB": ["Based", "on", "patient", "enrollment", "reports", "and", "services", "provided,", "we", "may", "periodically", "adjust", "estimates", "for", "the", "clinical", "trial", "costs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item7_p2_s3", "idA": "908259_15_item7_p20_s5", "sentA": "The increase in other expenses for the year ended December 31, 2014 as compared to the year ended December 31, 2013 is due primarily to licensing fees.", "sentB": "The aim of using a VDA and an AA in combination, is for the VDA to directly cut-off the blood supply to the interior of the tumor, while the AA indirectly inhibits angiogenesis, which is the process by which new blood vessels form and re-vascularize the tumor.", "type": 1, "words": ["<tag1>", "The", "increase", "in", "other", "expenses", "for", "the", "year", "ended", "December", "31,", "2014", "as", "compared", "to", "the", "year", "ended", "December", "31,", "2013", "is", "due", "primarily", "to", "licensing", "fees.", "<tag2>", "The", "aim", "of", "using", "a", "VDA", "and", "an", "AA", "in", "combination,", "is", "for", "the", "VDA", "to", "directly", "cut-off", "the", "blood", "supply", "to", "the", "interior", "of", "the", "tumor,", "while", "the", "AA", "indirectly", "inhibits", "angiogenesis,", "which", "is", "the", "process", "by", "which", "new", "blood", "vessels", "form", "and", "re-vascularize", "the", "tumor.", "<tag3>"], "wordsA": ["The", "increase", "in", "other", "expenses", "for", "the", "year", "ended", "December", "31,", "2014", "as", "compared", "to", "the", "year", "ended", "December", "31,", "2013", "is", "due", "primarily", "to", "licensing", "fees."], "wordsB": ["The", "aim", "of", "using", "a", "VDA", "and", "an", "AA", "in", "combination,", "is", "for", "the", "VDA", "to", "directly", "cut-off", "the", "blood", "supply", "to", "the", "interior", "of", "the", "tumor,", "while", "the", "AA", "indirectly", "inhibits", "angiogenesis,", "which", "is", "the", "process", "by", "which", "new", "blood", "vessels", "form", "and", "re-vascularize", "the", "tumor."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item7_p21_s4", "idA": "908259_15_item7_p23_s0", "sentA": "Investment income primarily reflects increases and decrease in cash balances due to interest earned on our operating cash accounts.", "sentB": "Our cash and cash equivalents are maintained in U.S. dollar accounts.", "type": 1, "words": ["<tag1>", "Investment", "income", "primarily", "reflects", "increases", "and", "decrease", "in", "cash", "balances", "due", "to", "interest", "earned", "on", "our", "operating", "cash", "accounts.", "<tag2>", "Our", "cash", "and", "cash", "equivalents", "are", "maintained", "in", "U.S.", "dollar", "accounts.", "<tag3>"], "wordsA": ["Investment", "income", "primarily", "reflects", "increases", "and", "decrease", "in", "cash", "balances", "due", "to", "interest", "earned", "on", "our", "operating", "cash", "accounts."], "wordsB": ["Our", "cash", "and", "cash", "equivalents", "are", "maintained", "in", "U.S.", "dollar", "accounts."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item7_p13_s4", "idA": "908259_15_item7_p24_s9", "sentA": "The following table summarizes our cash flow activities for the periods indicated, in thousands:", "sentB": "Changes in employee stock-based compensation were not significant between the periods presented.", "type": 1, "words": ["<tag1>", "The", "following", "table", "summarizes", "our", "cash", "flow", "activities", "for", "the", "periods", "indicated,", "in", "thousands:", "<tag2>", "Changes", "in", "employee", "stock-based", "compensation", "were", "not", "significant", "between", "the", "periods", "presented.", "<tag3>"], "wordsA": ["The", "following", "table", "summarizes", "our", "cash", "flow", "activities", "for", "the", "periods", "indicated,", "in", "thousands:"], "wordsB": ["Changes", "in", "employee", "stock-based", "compensation", "were", "not", "significant", "between", "the", "periods", "presented."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item7_p11_s0", "idA": "908259_15_item7_p38_s1", "sentA": "Investors purchased shares of our common stock, at a price per share of $1.7125.", "sentB": "Drug manufacturing expenses consist primarily of costs paid to third-party manufacturers for production of our investigational drugs.", "type": 1, "words": ["<tag1>", "Investors", "purchased", "shares", "of", "our", "common", "stock,", "at", "a", "price", "per", "share", "of", "$1.7125.", "<tag2>", "Drug", "manufacturing", "expenses", "consist", "primarily", "of", "costs", "paid", "to", "third-party", "manufacturers", "for", "production", "of", "our", "investigational", "drugs.", "<tag3>"], "wordsA": ["Investors", "purchased", "shares", "of", "our", "common", "stock,", "at", "a", "price", "per", "share", "of", "$1.7125."], "wordsB": ["Drug", "manufacturing", "expenses", "consist", "primarily", "of", "costs", "paid", "to", "third-party", "manufacturers", "for", "production", "of", "our", "investigational", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item7_p5_s8", "idA": "908259_15_item7_p42_s0", "sentA": "Payments under clinical development and related commitments are based on the completion of activities as specified in the contract.", "sentB": "Also included in clinical trial expenses are costs based on the level of patient enrollment into the clinical trial and the actual services performed under the related clinical trial agreement.", "type": 1, "words": ["<tag1>", "Payments", "under", "clinical", "development", "and", "related", "commitments", "are", "based", "on", "the", "completion", "of", "activities", "as", "specified", "in", "the", "contract.", "<tag2>", "Also", "included", "in", "clinical", "trial", "expenses", "are", "costs", "based", "on", "the", "level", "of", "patient", "enrollment", "into", "the", "clinical", "trial", "and", "the", "actual", "services", "performed", "under", "the", "related", "clinical", "trial", "agreement.", "<tag3>"], "wordsA": ["Payments", "under", "clinical", "development", "and", "related", "commitments", "are", "based", "on", "the", "completion", "of", "activities", "as", "specified", "in", "the", "contract."], "wordsB": ["Also", "included", "in", "clinical", "trial", "expenses", "are", "costs", "based", "on", "the", "level", "of", "patient", "enrollment", "into", "the", "clinical", "trial", "and", "the", "actual", "services", "performed", "under", "the", "related", "clinical", "trial", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item7_p18_s8", "idA": "908259_15_item7_p45_s1", "sentA": "Either party may terminate the license upon material default of the other party.", "sentB": "In addition, we may terminate the agreement by either (i) determining that filing for regulatory approval is not warranted or economically feasible by the clinical testing date or (ii) by providing two months written notice of our intent to terminate the agreement.", "type": 1, "words": ["<tag1>", "Either", "party", "may", "terminate", "the", "license", "upon", "material", "default", "of", "the", "other", "party.", "<tag2>", "In", "addition,", "we", "may", "terminate", "the", "agreement", "by", "either", "(i)", "determining", "that", "filing", "for", "regulatory", "approval", "is", "not", "warranted", "or", "economically", "feasible", "by", "the", "clinical", "testing", "date", "or", "(ii)", "by", "providing", "two", "months", "written", "notice", "of", "our", "intent", "to", "terminate", "the", "agreement.", "<tag3>"], "wordsA": ["Either", "party", "may", "terminate", "the", "license", "upon", "material", "default", "of", "the", "other", "party."], "wordsB": ["In", "addition,", "we", "may", "terminate", "the", "agreement", "by", "either", "(i)", "determining", "that", "filing", "for", "regulatory", "approval", "is", "not", "warranted", "or", "economically", "feasible", "by", "the", "clinical", "testing", "date", "or", "(ii)", "by", "providing", "two", "months", "written", "notice", "of", "our", "intent", "to", "terminate", "the", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item7_p2_s4", "idA": "908259_15_item7_p45_s1", "sentA": "Either party may terminate the license upon material default of the other party.", "sentB": "Our current VDA development plans are focused on this combination so that the mechanism of action of each drug would complement that of the other disrupting tumor blood supply in two different ways instead of just one.", "type": 1, "words": ["<tag1>", "Either", "party", "may", "terminate", "the", "license", "upon", "material", "default", "of", "the", "other", "party.", "<tag2>", "Our", "current", "VDA", "development", "plans", "are", "focused", "on", "this", "combination", "so", "that", "the", "mechanism", "of", "action", "of", "each", "drug", "would", "complement", "that", "of", "the", "other", "disrupting", "tumor", "blood", "supply", "in", "two", "different", "ways", "instead", "of", "just", "one.", "<tag3>"], "wordsA": ["Either", "party", "may", "terminate", "the", "license", "upon", "material", "default", "of", "the", "other", "party."], "wordsB": ["Our", "current", "VDA", "development", "plans", "are", "focused", "on", "this", "combination", "so", "that", "the", "mechanism", "of", "action", "of", "each", "drug", "would", "complement", "that", "of", "the", "other", "disrupting", "tumor", "blood", "supply", "in", "two", "different", "ways", "instead", "of", "just", "one."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item7_p5_s9", "idA": "908259_15_item7_p7_s7", "sentA": "We may be able to sell more shares under this agreement depending on several factors including our stock price, the number of shares of our common stock outstanding as well as the timing of the occurrence of the sales.", "sentB": "Changes in clinical trial assumptions, such as the length of time estimated to enroll all patients, rate of screening failures, patient drop-out rates, number and nature of adverse event reports and the total number of patients enrolled can impact the average and expected cost per patient and the overall cost of the clinical trial.", "type": 1, "words": ["<tag1>", "We", "may", "be", "able", "to", "sell", "more", "shares", "under", "this", "agreement", "depending", "on", "several", "factors", "including", "our", "stock", "price,", "the", "number", "of", "shares", "of", "our", "common", "stock", "outstanding", "as", "well", "as", "the", "timing", "of", "the", "occurrence", "of", "the", "sales.", "<tag2>", "Changes", "in", "clinical", "trial", "assumptions,", "such", "as", "the", "length", "of", "time", "estimated", "to", "enroll", "all", "patients,", "rate", "of", "screening", "failures,", "patient", "drop-out", "rates,", "number", "and", "nature", "of", "adverse", "event", "reports", "and", "the", "total", "number", "of", "patients", "enrolled", "can", "impact", "the", "average", "and", "expected", "cost", "per", "patient", "and", "the", "overall", "cost", "of", "the", "clinical", "trial.", "<tag3>"], "wordsA": ["We", "may", "be", "able", "to", "sell", "more", "shares", "under", "this", "agreement", "depending", "on", "several", "factors", "including", "our", "stock", "price,", "the", "number", "of", "shares", "of", "our", "common", "stock", "outstanding", "as", "well", "as", "the", "timing", "of", "the", "occurrence", "of", "the", "sales."], "wordsB": ["Changes", "in", "clinical", "trial", "assumptions,", "such", "as", "the", "length", "of", "time", "estimated", "to", "enroll", "all", "patients,", "rate", "of", "screening", "failures,", "patient", "drop-out", "rates,", "number", "and", "nature", "of", "adverse", "event", "reports", "and", "the", "total", "number", "of", "patients", "enrolled", "can", "impact", "the", "average", "and", "expected", "cost", "per", "patient", "and", "the", "overall", "cost", "of", "the", "clinical", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item7_p4_s3", "idA": "908259_15_item7_p8_s9", "sentA": "On an ongoing basis, we evaluate our estimates and judgments, including those related to intangible assets.", "sentB": "We periodically review our estimates in light of changes in circumstances, facts and experience.", "type": 1, "words": ["<tag1>", "On", "an", "ongoing", "basis,", "we", "evaluate", "our", "estimates", "and", "judgments,", "including", "those", "related", "to", "intangible", "assets.", "<tag2>", "We", "periodically", "review", "our", "estimates", "in", "light", "of", "changes", "in", "circumstances,", "facts", "and", "experience.", "<tag3>"], "wordsA": ["On", "an", "ongoing", "basis,", "we", "evaluate", "our", "estimates", "and", "judgments,", "including", "those", "related", "to", "intangible", "assets."], "wordsB": ["We", "periodically", "review", "our", "estimates", "in", "light", "of", "changes", "in", "circumstances,", "facts", "and", "experience."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item7_p10_s2", "idA": "908259_16_item7_p10_s1", "sentA": "These increases were partially offset by lower drug manufacturing expenses since the drug product required for our 2015 clinical programs was manufactured in 2014.", "sentB": "FOCUS currently represents the most advanced clinical study for our lead investigational drug.", "type": 1, "words": ["<tag1>", "These", "increases", "were", "partially", "offset", "by", "lower", "drug", "manufacturing", "expenses", "since", "the", "drug", "product", "required", "for", "our", "2015", "clinical", "programs", "was", "manufactured", "in", "2014.", "<tag2>", "FOCUS", "currently", "represents", "the", "most", "advanced", "clinical", "study", "for", "our", "lead", "investigational", "drug.", "<tag3>"], "wordsA": ["These", "increases", "were", "partially", "offset", "by", "lower", "drug", "manufacturing", "expenses", "since", "the", "drug", "product", "required", "for", "our", "2015", "clinical", "programs", "was", "manufactured", "in", "2014."], "wordsB": ["FOCUS", "currently", "represents", "the", "most", "advanced", "clinical", "study", "for", "our", "lead", "investigational", "drug."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item7_p13_s13", "idA": "908259_16_item7_p14_s2", "sentA": "Although general and administrative expenses decreased in 2015 compared to 2014, we expect general and administrative expenses to increase in 2016 to support our planned increase in research and development, as well as for additional business development and investor relations efforts.", "sentB": "No cash was provided by financing activities in 2016.", "type": 1, "words": ["<tag1>", "Although", "general", "and", "administrative", "expenses", "decreased", "in", "2015", "compared", "to", "2014,", "we", "expect", "general", "and", "administrative", "expenses", "to", "increase", "in", "2016", "to", "support", "our", "planned", "increase", "in", "research", "and", "development,", "as", "well", "as", "for", "additional", "business", "development", "and", "investor", "relations", "efforts.", "<tag2>", "No", "cash", "was", "provided", "by", "financing", "activities", "in", "2016.", "<tag3>"], "wordsA": ["Although", "general", "and", "administrative", "expenses", "decreased", "in", "2015", "compared", "to", "2014,", "we", "expect", "general", "and", "administrative", "expenses", "to", "increase", "in", "2016", "to", "support", "our", "planned", "increase", "in", "research", "and", "development,", "as", "well", "as", "for", "additional", "business", "development", "and", "investor", "relations", "efforts."], "wordsB": ["No", "cash", "was", "provided", "by", "financing", "activities", "in", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item7_p10_s4", "idA": "908259_16_item7_p2_s7", "sentA": "Based on the positive results of this clinical trial, we are initiating a phase 2/3 clinical trial in platinum-resistant ovarian cancer, which will compare treatment with CA4P, bevacizumab and chemotherapy to treatment with bevacizumab and chemotherapy.", "sentB": "In addition, higher costs were incurred for OX1222, evaluating OXi4503 in AML, after this clinical trial was expanded in late 2015.", "type": 1, "words": ["<tag1>", "Based", "on", "the", "positive", "results", "of", "this", "clinical", "trial,", "we", "are", "initiating", "a", "phase", "2/3", "clinical", "trial", "in", "platinum-resistant", "ovarian", "cancer,", "which", "will", "compare", "treatment", "with", "CA4P,", "bevacizumab", "and", "chemotherapy", "to", "treatment", "with", "bevacizumab", "and", "chemotherapy.", "<tag2>", "In", "addition,", "higher", "costs", "were", "incurred", "for", "OX1222,", "evaluating", "OXi4503", "in", "AML,", "after", "this", "clinical", "trial", "was", "expanded", "in", "late", "2015.", "<tag3>"], "wordsA": ["Based", "on", "the", "positive", "results", "of", "this", "clinical", "trial,", "we", "are", "initiating", "a", "phase", "2/3", "clinical", "trial", "in", "platinum-resistant", "ovarian", "cancer,", "which", "will", "compare", "treatment", "with", "CA4P,", "bevacizumab", "and", "chemotherapy", "to", "treatment", "with", "bevacizumab", "and", "chemotherapy."], "wordsB": ["In", "addition,", "higher", "costs", "were", "incurred", "for", "OX1222,", "evaluating", "OXi4503", "in", "AML,", "after", "this", "clinical", "trial", "was", "expanded", "in", "late", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item7_p10_s7", "idA": "908259_16_item7_p3_s2", "sentA": "These activities included supporting the CA4P ovarian cancer phase 2 clinical trial conducted by the GOG, the investigator-sponsored OXi4503 phase 1 clinical trial in AML, our distribution agreement for the compassionate use of CA4P in anaplastic thyroid cancer, or ATC, in Europe, and the manufacture of CA4P for subsequent clinical trials.", "sentB": "In addition to supporting the FOCUS study, we hired these employees to reduce our reliance on outside consultants to conduct similar work.", "type": 1, "words": ["<tag1>", "These", "activities", "included", "supporting", "the", "CA4P", "ovarian", "cancer", "phase", "2", "clinical", "trial", "conducted", "by", "the", "GOG,", "the", "investigator-sponsored", "OXi4503", "phase", "1", "clinical", "trial", "in", "AML,", "our", "distribution", "agreement", "for", "the", "compassionate", "use", "of", "CA4P", "in", "anaplastic", "thyroid", "cancer,", "or", "ATC,", "in", "Europe,", "and", "the", "manufacture", "of", "CA4P", "for", "subsequent", "clinical", "trials.", "<tag2>", "In", "addition", "to", "supporting", "the", "FOCUS", "study,", "we", "hired", "these", "employees", "to", "reduce", "our", "reliance", "on", "outside", "consultants", "to", "conduct", "similar", "work.", "<tag3>"], "wordsA": ["These", "activities", "included", "supporting", "the", "CA4P", "ovarian", "cancer", "phase", "2", "clinical", "trial", "conducted", "by", "the", "GOG,", "the", "investigator-sponsored", "OXi4503", "phase", "1", "clinical", "trial", "in", "AML,", "our", "distribution", "agreement", "for", "the", "compassionate", "use", "of", "CA4P", "in", "anaplastic", "thyroid", "cancer,", "or", "ATC,", "in", "Europe,", "and", "the", "manufacture", "of", "CA4P", "for", "subsequent", "clinical", "trials."], "wordsB": ["In", "addition", "to", "supporting", "the", "FOCUS", "study,", "we", "hired", "these", "employees", "to", "reduce", "our", "reliance", "on", "outside", "consultants", "to", "conduct", "similar", "work."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item7_p3_s4", "idA": "908259_17_item7_p0_s0", "sentA": "Our management s discussion and analysis of financial condition and results of operations contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.", "sentB": "On April 12, 2018, we closed on net proceeds of approximately $2.4 million from a private placement transaction, or the Private Placement.", "type": 1, "words": ["<tag1>", "Our", "management", "s", "discussion", "and", "analysis", "of", "financial", "condition", "and", "results", "of", "operations", "contains", "forward-looking", "statements", "within", "the", "meaning", "of", "the", "Private", "Securities", "Litigation", "Reform", "Act", "of", "1995.", "<tag2>", "On", "April", "12,", "2018,", "we", "closed", "on", "net", "proceeds", "of", "approximately", "$2.4", "million", "from", "a", "private", "placement", "transaction,", "or", "the", "Private", "Placement.", "<tag3>"], "wordsA": ["Our", "management", "s", "discussion", "and", "analysis", "of", "financial", "condition", "and", "results", "of", "operations", "contains", "forward-looking", "statements", "within", "the", "meaning", "of", "the", "Private", "Securities", "Litigation", "Reform", "Act", "of", "1995."], "wordsB": ["On", "April", "12,", "2018,", "we", "closed", "on", "net", "proceeds", "of", "approximately", "$2.4", "million", "from", "a", "private", "placement", "transaction,", "or", "the", "Private", "Placement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item7_p3_s5", "idA": "908259_17_item7_p0_s0", "sentA": "Our management s discussion and analysis of financial condition and results of operations contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.", "sentB": "In the Private Placement, we sold 58.5 units at a purchase price of $50,000 per unit.", "type": 1, "words": ["<tag1>", "Our", "management", "s", "discussion", "and", "analysis", "of", "financial", "condition", "and", "results", "of", "operations", "contains", "forward-looking", "statements", "within", "the", "meaning", "of", "the", "Private", "Securities", "Litigation", "Reform", "Act", "of", "1995.", "<tag2>", "In", "the", "Private", "Placement,", "we", "sold", "58.5", "units", "at", "a", "purchase", "price", "of", "$50,000", "per", "unit.", "<tag3>"], "wordsA": ["Our", "management", "s", "discussion", "and", "analysis", "of", "financial", "condition", "and", "results", "of", "operations", "contains", "forward-looking", "statements", "within", "the", "meaning", "of", "the", "Private", "Securities", "Litigation", "Reform", "Act", "of", "1995."], "wordsB": ["In", "the", "Private", "Placement,", "we", "sold", "58.5", "units", "at", "a", "purchase", "price", "of", "$50,000", "per", "unit."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item7_p1_s3", "idA": "908259_17_item7_p11_s5", "sentA": "Other expenses include facility related expenses and licensing fees which decreased in 2016 compared to 2015 primarily due to lower licensing fees paid for rights to our drug product candidates.", "sentB": "Following fifth dose cohort, we paused enrollment in the study due to our lack of available cash to complete further testing.", "type": 1, "words": ["<tag1>", "Other", "expenses", "include", "facility", "related", "expenses", "and", "licensing", "fees", "which", "decreased", "in", "2016", "compared", "to", "2015", "primarily", "due", "to", "lower", "licensing", "fees", "paid", "for", "rights", "to", "our", "drug", "product", "candidates.", "<tag2>", "Following", "fifth", "dose", "cohort,", "we", "paused", "enrollment", "in", "the", "study", "due", "to", "our", "lack", "of", "available", "cash", "to", "complete", "further", "testing.", "<tag3>"], "wordsA": ["Other", "expenses", "include", "facility", "related", "expenses", "and", "licensing", "fees", "which", "decreased", "in", "2016", "compared", "to", "2015", "primarily", "due", "to", "lower", "licensing", "fees", "paid", "for", "rights", "to", "our", "drug", "product", "candidates."], "wordsB": ["Following", "fifth", "dose", "cohort,", "we", "paused", "enrollment", "in", "the", "study", "due", "to", "our", "lack", "of", "available", "cash", "to", "complete", "further", "testing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item7_p11_s15", "idA": "908259_17_item7_p11_s6", "sentA": "Because we plan to continue our FOCUS study of CA4P in platinum-resistant ovarian cancer and continue with our OX1222 study of OXi4503 in AML in 2017, subject to available funding to continue those trials, we expect research and development expenses to increase in 2017, particularly for clinical studies.", "sentB": "We expect to prioritize obtaining additional clinical data for our OX1222 Study of OXi4503 in relapsed/refractory acute myeloid leukemia and obtaining initial data combining CA4P with an approved immuno-oncology agent.", "type": 1, "words": ["<tag1>", "Because", "we", "plan", "to", "continue", "our", "FOCUS", "study", "of", "CA4P", "in", "platinum-resistant", "ovarian", "cancer", "and", "continue", "with", "our", "OX1222", "study", "of", "OXi4503", "in", "AML", "in", "2017,", "subject", "to", "available", "funding", "to", "continue", "those", "trials,", "we", "expect", "research", "and", "development", "expenses", "to", "increase", "in", "2017,", "particularly", "for", "clinical", "studies.", "<tag2>", "We", "expect", "to", "prioritize", "obtaining", "additional", "clinical", "data", "for", "our", "OX1222", "Study", "of", "OXi4503", "in", "relapsed/refractory", "acute", "myeloid", "leukemia", "and", "obtaining", "initial", "data", "combining", "CA4P", "with", "an", "approved", "immuno-oncology", "agent.", "<tag3>"], "wordsA": ["Because", "we", "plan", "to", "continue", "our", "FOCUS", "study", "of", "CA4P", "in", "platinum-resistant", "ovarian", "cancer", "and", "continue", "with", "our", "OX1222", "study", "of", "OXi4503", "in", "AML", "in", "2017,", "subject", "to", "available", "funding", "to", "continue", "those", "trials,", "we", "expect", "research", "and", "development", "expenses", "to", "increase", "in", "2017,", "particularly", "for", "clinical", "studies."], "wordsB": ["We", "expect", "to", "prioritize", "obtaining", "additional", "clinical", "data", "for", "our", "OX1222", "Study", "of", "OXi4503", "in", "relapsed/refractory", "acute", "myeloid", "leukemia", "and", "obtaining", "initial", "data", "combining", "CA4P", "with", "an", "approved", "immuno-oncology", "agent."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item7_p3_s3", "idA": "908259_17_item7_p13_s11", "sentA": "If we are able to secure additional funding to continue our operations, we expect to incur significant additional costs and expenses over at least the next several years as a result of our plans to develop VDAs for the treatment of cancer, including continuing our existing clinical trials as well as conducting new, additional clinical trials and anticipated research and development expenditures.", "sentB": "To date the Company has not achieved the specified level of additional funding to reinstate the salaries.", "type": 1, "words": ["<tag1>", "If", "we", "are", "able", "to", "secure", "additional", "funding", "to", "continue", "our", "operations,", "we", "expect", "to", "incur", "significant", "additional", "costs", "and", "expenses", "over", "at", "least", "the", "next", "several", "years", "as", "a", "result", "of", "our", "plans", "to", "develop", "VDAs", "for", "the", "treatment", "of", "cancer,", "including", "continuing", "our", "existing", "clinical", "trials", "as", "well", "as", "conducting", "new,", "additional", "clinical", "trials", "and", "anticipated", "research", "and", "development", "expenditures.", "<tag2>", "To", "date", "the", "Company", "has", "not", "achieved", "the", "specified", "level", "of", "additional", "funding", "to", "reinstate", "the", "salaries.", "<tag3>"], "wordsA": ["If", "we", "are", "able", "to", "secure", "additional", "funding", "to", "continue", "our", "operations,", "we", "expect", "to", "incur", "significant", "additional", "costs", "and", "expenses", "over", "at", "least", "the", "next", "several", "years", "as", "a", "result", "of", "our", "plans", "to", "develop", "VDAs", "for", "the", "treatment", "of", "cancer,", "including", "continuing", "our", "existing", "clinical", "trials", "as", "well", "as", "conducting", "new,", "additional", "clinical", "trials", "and", "anticipated", "research", "and", "development", "expenditures."], "wordsB": ["To", "date", "the", "Company", "has", "not", "achieved", "the", "specified", "level", "of", "additional", "funding", "to", "reinstate", "the", "salaries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item7_p2_s0", "idA": "908259_17_item7_p13_s15", "sentA": "We will require additional capital before we can complete all planned clinical trials and development of CA4P and OXi4503.", "sentB": "Recent preclinical data has shown treatment with the combination of CA4P and an anti-CTLA-4 antibody nearly doubles the amount of tumor necrosis (mean = 63.9%) compared to treatment with an anti-CTLA-4 antibody alone (32.8%), CA4P alone (37.3%) or vehicle control (25.8%) in a preclinical CT-26 mouse colon cancer model.", "type": 1, "words": ["<tag1>", "We", "will", "require", "additional", "capital", "before", "we", "can", "complete", "all", "planned", "clinical", "trials", "and", "development", "of", "CA4P", "and", "OXi4503.", "<tag2>", "Recent", "preclinical", "data", "has", "shown", "treatment", "with", "the", "combination", "of", "CA4P", "and", "an", "anti-CTLA-4", "antibody", "nearly", "doubles", "the", "amount", "of", "tumor", "necrosis", "(mean", "=", "63.9%)", "compared", "to", "treatment", "with", "an", "anti-CTLA-4", "antibody", "alone", "(32.8%),", "CA4P", "alone", "(37.3%)", "or", "vehicle", "control", "(25.8%)", "in", "a", "preclinical", "CT-26", "mouse", "colon", "cancer", "model.", "<tag3>"], "wordsA": ["We", "will", "require", "additional", "capital", "before", "we", "can", "complete", "all", "planned", "clinical", "trials", "and", "development", "of", "CA4P", "and", "OXi4503."], "wordsB": ["Recent", "preclinical", "data", "has", "shown", "treatment", "with", "the", "combination", "of", "CA4P", "and", "an", "anti-CTLA-4", "antibody", "nearly", "doubles", "the", "amount", "of", "tumor", "necrosis", "(mean", "=", "63.9%)", "compared", "to", "treatment", "with", "an", "anti-CTLA-4", "antibody", "alone", "(32.8%),", "CA4P", "alone", "(37.3%)", "or", "vehicle", "control", "(25.8%)", "in", "a", "preclinical", "CT-26", "mouse", "colon", "cancer", "model."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item7_p2_s2", "idA": "908259_17_item7_p3_s0", "sentA": "VDA development plans are focused on this combination so that the mechanism of action of each drug would complement that of the other disrupting tumor blood supply in two different ways instead of just one.", "sentB": "The data also showed that the distribution of the beneficial CD8+T lymphocyte cells was observed throughout the tumor - in both the tumor rim and tumor core.", "type": 1, "words": ["<tag1>", "VDA", "development", "plans", "are", "focused", "on", "this", "combination", "so", "that", "the", "mechanism", "of", "action", "of", "each", "drug", "would", "complement", "that", "of", "the", "other", "disrupting", "tumor", "blood", "supply", "in", "two", "different", "ways", "instead", "of", "just", "one.", "<tag2>", "The", "data", "also", "showed", "that", "the", "distribution", "of", "the", "beneficial", "CD8+T", "lymphocyte", "cells", "was", "observed", "throughout", "the", "tumor", "-", "in", "both", "the", "tumor", "rim", "and", "tumor", "core.", "<tag3>"], "wordsA": ["VDA", "development", "plans", "are", "focused", "on", "this", "combination", "so", "that", "the", "mechanism", "of", "action", "of", "each", "drug", "would", "complement", "that", "of", "the", "other", "disrupting", "tumor", "blood", "supply", "in", "two", "different", "ways", "instead", "of", "just", "one."], "wordsB": ["The", "data", "also", "showed", "that", "the", "distribution", "of", "the", "beneficial", "CD8+T", "lymphocyte", "cells", "was", "observed", "throughout", "the", "tumor", "-", "in", "both", "the", "tumor", "rim", "and", "tumor", "core."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item7_p2_s1", "idA": "908259_17_item7_p3_s2", "sentA": "Our lead compound is CA4P. The largest clinical trial of CA4P conducted to date was a phase 2 clinical trial in recurrent ovarian cancer sponsored by the Gynecologic Oncology Group, or GOG, which was completed in 2014 and met its primary endpoint by demonstrating an improvement in progression-free survival for the patients who received CA4P. This trial, referred to as GOG-0186I, compared treatment with CA4P plus bevacizumab to treatment with bevacizumab alone.", "sentB": "Results from this most recent analysis preclinically confirmed our earlier findings which showed that treatment with CA4P and an approved immuno-oncology agent resulted in increased overall median numbers of tumor infiltrating white blood cells, T cells and CD8+ T lymphocytes.", "type": 1, "words": ["<tag1>", "Our", "lead", "compound", "is", "CA4P.", "The", "largest", "clinical", "trial", "of", "CA4P", "conducted", "to", "date", "was", "a", "phase", "2", "clinical", "trial", "in", "recurrent", "ovarian", "cancer", "sponsored", "by", "the", "Gynecologic", "Oncology", "Group,", "or", "GOG,", "which", "was", "completed", "in", "2014", "and", "met", "its", "primary", "endpoint", "by", "demonstrating", "an", "improvement", "in", "progression-free", "survival", "for", "the", "patients", "who", "received", "CA4P.", "This", "trial,", "referred", "to", "as", "GOG-0186I,", "compared", "treatment", "with", "CA4P", "plus", "bevacizumab", "to", "treatment", "with", "bevacizumab", "alone.", "<tag2>", "Results", "from", "this", "most", "recent", "analysis", "preclinically", "confirmed", "our", "earlier", "findings", "which", "showed", "that", "treatment", "with", "CA4P", "and", "an", "approved", "immuno-oncology", "agent", "resulted", "in", "increased", "overall", "median", "numbers", "of", "tumor", "infiltrating", "white", "blood", "cells,", "T", "cells", "and", "CD8+", "T", "lymphocytes.", "<tag3>"], "wordsA": ["Our", "lead", "compound", "is", "CA4P.", "The", "largest", "clinical", "trial", "of", "CA4P", "conducted", "to", "date", "was", "a", "phase", "2", "clinical", "trial", "in", "recurrent", "ovarian", "cancer", "sponsored", "by", "the", "Gynecologic", "Oncology", "Group,", "or", "GOG,", "which", "was", "completed", "in", "2014", "and", "met", "its", "primary", "endpoint", "by", "demonstrating", "an", "improvement", "in", "progression-free", "survival", "for", "the", "patients", "who", "received", "CA4P.", "This", "trial,", "referred", "to", "as", "GOG-0186I,", "compared", "treatment", "with", "CA4P", "plus", "bevacizumab", "to", "treatment", "with", "bevacizumab", "alone."], "wordsB": ["Results", "from", "this", "most", "recent", "analysis", "preclinically", "confirmed", "our", "earlier", "findings", "which", "showed", "that", "treatment", "with", "CA4P", "and", "an", "approved", "immuno-oncology", "agent", "resulted", "in", "increased", "overall", "median", "numbers", "of", "tumor", "infiltrating", "white", "blood", "cells,", "T", "cells", "and", "CD8+", "T", "lymphocytes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item7_p1_s1", "idA": "908259_17_item7_p3_s3", "sentA": "Based on the positive results of this clinical trial, we are conducting a two-stage, phase 2/3 clinical trial in platinum-resistant ovarian cancer, which will compare treatment with CA4P, bevacizumab and chemotherapy, or the active treatment arm, to treatment with bevacizumab and chemotherapy, or the control arm.", "sentB": "In this clinical trial we have most recently observed that two of four patients in the fifth dose cohort of an ascending-dose study experienced complete remissions of their disease after just one cycle of treatment with 9.76 mg/m2 of OXi4503.", "type": 1, "words": ["<tag1>", "Based", "on", "the", "positive", "results", "of", "this", "clinical", "trial,", "we", "are", "conducting", "a", "two-stage,", "phase", "2/3", "clinical", "trial", "in", "platinum-resistant", "ovarian", "cancer,", "which", "will", "compare", "treatment", "with", "CA4P,", "bevacizumab", "and", "chemotherapy,", "or", "the", "active", "treatment", "arm,", "to", "treatment", "with", "bevacizumab", "and", "chemotherapy,", "or", "the", "control", "arm.", "<tag2>", "In", "this", "clinical", "trial", "we", "have", "most", "recently", "observed", "that", "two", "of", "four", "patients", "in", "the", "fifth", "dose", "cohort", "of", "an", "ascending-dose", "study", "experienced", "complete", "remissions", "of", "their", "disease", "after", "just", "one", "cycle", "of", "treatment", "with", "9.76", "mg/m2", "of", "OXi4503.", "<tag3>"], "wordsA": ["Based", "on", "the", "positive", "results", "of", "this", "clinical", "trial,", "we", "are", "conducting", "a", "two-stage,", "phase", "2/3", "clinical", "trial", "in", "platinum-resistant", "ovarian", "cancer,", "which", "will", "compare", "treatment", "with", "CA4P,", "bevacizumab", "and", "chemotherapy,", "or", "the", "active", "treatment", "arm,", "to", "treatment", "with", "bevacizumab", "and", "chemotherapy,", "or", "the", "control", "arm."], "wordsB": ["In", "this", "clinical", "trial", "we", "have", "most", "recently", "observed", "that", "two", "of", "four", "patients", "in", "the", "fifth", "dose", "cohort", "of", "an", "ascending-dose", "study", "experienced", "complete", "remissions", "of", "their", "disease", "after", "just", "one", "cycle", "of", "treatment", "with", "9.76", "mg/m2", "of", "OXi4503."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item7_p1_s2", "idA": "908259_17_item7_p3_s5", "sentA": "Our second compound, OXi4503, is being studied in combination with cytarabine in a phase 1/2 clinical trial in the United States in patients with relapsed or refractory acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS).", "sentB": "Earlier in the clinical trial, at lower doses of our drug, we observed three patients with complete remissions following two cycles of treatment and two patients with partial remissions.", "type": 1, "words": ["<tag1>", "Our", "second", "compound,", "OXi4503,", "is", "being", "studied", "in", "combination", "with", "cytarabine", "in", "a", "phase", "1/2", "clinical", "trial", "in", "the", "United", "States", "in", "patients", "with", "relapsed", "or", "refractory", "acute", "myelogenous", "leukemia", "(AML)", "or", "myelodysplastic", "syndromes", "(MDS).", "<tag2>", "Earlier", "in", "the", "clinical", "trial,", "at", "lower", "doses", "of", "our", "drug,", "we", "observed", "three", "patients", "with", "complete", "remissions", "following", "two", "cycles", "of", "treatment", "and", "two", "patients", "with", "partial", "remissions.", "<tag3>"], "wordsA": ["Our", "second", "compound,", "OXi4503,", "is", "being", "studied", "in", "combination", "with", "cytarabine", "in", "a", "phase", "1/2", "clinical", "trial", "in", "the", "United", "States", "in", "patients", "with", "relapsed", "or", "refractory", "acute", "myelogenous", "leukemia", "(AML)", "or", "myelodysplastic", "syndromes", "(MDS)."], "wordsB": ["Earlier", "in", "the", "clinical", "trial,", "at", "lower", "doses", "of", "our", "drug,", "we", "observed", "three", "patients", "with", "complete", "remissions", "following", "two", "cycles", "of", "treatment", "and", "two", "patients", "with", "partial", "remissions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item7_p3_s2", "idA": "908259_17_item7_p4_s4", "sentA": "The effects of material revisions in estimates are reflected in the financial statements prospectively from the date of the change in estimate.", "sentB": "Thereafter, effective October 2, 2017, we terminated the employment of over half of our workforce and reduced the salaries of our executive officers by 50%, with reinstatement to previous compensation levels contingent on a change in control of the Company or the Company raising additional funding of at least $4 million.", "type": 1, "words": ["<tag1>", "The", "effects", "of", "material", "revisions", "in", "estimates", "are", "reflected", "in", "the", "financial", "statements", "prospectively", "from", "the", "date", "of", "the", "change", "in", "estimate.", "<tag2>", "Thereafter,", "effective", "October", "2,", "2017,", "we", "terminated", "the", "employment", "of", "over", "half", "of", "our", "workforce", "and", "reduced", "the", "salaries", "of", "our", "executive", "officers", "by", "50%,", "with", "reinstatement", "to", "previous", "compensation", "levels", "contingent", "on", "a", "change", "in", "control", "of", "the", "Company", "or", "the", "Company", "raising", "additional", "funding", "of", "at", "least", "$4", "million.", "<tag3>"], "wordsA": ["The", "effects", "of", "material", "revisions", "in", "estimates", "are", "reflected", "in", "the", "financial", "statements", "prospectively", "from", "the", "date", "of", "the", "change", "in", "estimate."], "wordsB": ["Thereafter,", "effective", "October", "2,", "2017,", "we", "terminated", "the", "employment", "of", "over", "half", "of", "our", "workforce", "and", "reduced", "the", "salaries", "of", "our", "executive", "officers", "by", "50%,", "with", "reinstatement", "to", "previous", "compensation", "levels", "contingent", "on", "a", "change", "in", "control", "of", "the", "Company", "or", "the", "Company", "raising", "additional", "funding", "of", "at", "least", "$4", "million."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item7_p3_s8", "idA": "908259_17_item7_p7_s3", "sentA": "Accordingly, we use a Black-Scholes option pricing model to derive an estimated fair value of the stock options which we issue.", "sentB": "The exercise price of the warrants will only be payable in cash, with no cashless exercise provisions.", "type": 1, "words": ["<tag1>", "Accordingly,", "we", "use", "a", "Black-Scholes", "option", "pricing", "model", "to", "derive", "an", "estimated", "fair", "value", "of", "the", "stock", "options", "which", "we", "issue.", "<tag2>", "The", "exercise", "price", "of", "the", "warrants", "will", "only", "be", "payable", "in", "cash,", "with", "no", "cashless", "exercise", "provisions.", "<tag3>"], "wordsA": ["Accordingly,", "we", "use", "a", "Black-Scholes", "option", "pricing", "model", "to", "derive", "an", "estimated", "fair", "value", "of", "the", "stock", "options", "which", "we", "issue."], "wordsB": ["The", "exercise", "price", "of", "the", "warrants", "will", "only", "be", "payable", "in", "cash,", "with", "no", "cashless", "exercise", "provisions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
